BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617-649. [PMID: 21039302 DOI: 10.3109/07853890.2010.518623] [Cited by in Crossref: 770] [Cited by in F6Publishing: 763] [Article Influence: 64.2] [Reference Citation Analysis]
Number Citing Articles
1 Liu X, Chen W, Shao W, Jiang Y, Cao Z, He W, Wu M, Chen Z, Ma J, Chen Y, Yu P, Zhang Y, Wang J. Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction. ESC Heart Fail 2022. [PMID: 35996808 DOI: 10.1002/ehf2.14087] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kostogrys RB, Franczyk-żarów M, Kus E, Topolska K. LCHP Diet Enriched with Cholesterol Promotes Non-Alcoholic Fatty Liver Disease in Wistar Rats. Applied Sciences 2022;12:8266. [DOI: 10.3390/app12168266] [Reference Citation Analysis]
3 Li R, Li Y, Yang X, Hu Y, Yu H, Li Y. Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibiting AMPK signaling pathway. J Transl Med 2022;20:341. [PMID: 35907871 DOI: 10.1186/s12967-022-03540-2] [Reference Citation Analysis]
4 Tan L, Shin S. Effects of oily fish and its fatty acid intake on non-alcoholic fatty liver disease development among South Korean adults. Front Nutr 2022;9:876909. [DOI: 10.3389/fnut.2022.876909] [Reference Citation Analysis]
5 Yagi C, Kusunoki Y, Tsunoda T, Murase T, Nakamura T, Osugi K, Ohigashi M, Morimoto A, Miyoshi A, Kakutani-Hatayama M, Kosaka-Hamamoto K, Kadoya M, Konishi K, Shoji T, Koyama H. Xanthine oxidoreductase activity is correlated with hepatic steatosis. Sci Rep 2022;12:12282. [PMID: 35854080 DOI: 10.1038/s41598-022-16688-0] [Reference Citation Analysis]
6 Li R, Zhou L, Chen C, Han X, Gao M, Cheng X, Li J. Sensitivity to thyroid hormones is associated with advanced fibrosis in euthyroid patients with non-alcoholic fatty liver disease: A cross-sectional study. Dig Liver Dis 2022:S1590-8658(22)00560-6. [PMID: 35853822 DOI: 10.1016/j.dld.2022.06.021] [Reference Citation Analysis]
7 Shao G, Liu Y, Lu L, Zhang G, Zhou W, Wu T, Wang L, Xu H, Ji G. The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products. Front Pharmacol 2022;13:944088. [DOI: 10.3389/fphar.2022.944088] [Reference Citation Analysis]
8 Roubidoux MA, Kaur JS, Rhoades DA. Health Disparities in Cancer Among American Indians and Alaska Natives. Acad Radiol 2022;29:1013-21. [PMID: 34802904 DOI: 10.1016/j.acra.2021.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Abdallah M, Brown L, Provenza J, Tariq R, Gowda S, Singal AK. Safety and efficacy of dyslipidemia treatment in NAFLD Patients: a Meta-analysis of randomized controlled trials. Ann Hepatol 2022;:100738. [PMID: 35781090 DOI: 10.1016/j.aohep.2022.100738] [Reference Citation Analysis]
10 Pacheco LS, Bradley RD, Anderson CAM, Allison MA. Changes in Biomarkers of Non-Alcoholic Fatty Liver Disease (NAFLD) upon Access to Avocados in Hispanic/Latino Adults: Secondary Data Analysis of a Cluster Randomized Controlled Trial. Nutrients 2022;14:2744. [DOI: 10.3390/nu14132744] [Reference Citation Analysis]
11 Sun Y, Hong L, Huang Z, Wang L, Xiong Y, Zong S, Zhang R, Liu J, Zang S. Fibrosis Risk in Nonalcoholic Fatty Liver Disease is Related to Chronic Kidney Disease in Aged Type 2 Diabetes Patients. J Clin Endocrinol Metab 2022:dgac382. [PMID: 35766414 DOI: 10.1210/clinem/dgac382] [Reference Citation Analysis]
12 Carteri RB, Grellert M, Borba DL, Marroni CA, Fernandes SA. Machine learning approaches using blood biomarkers in non-alcoholic fatty liver diseases. Artif Intell Gastroenterol 2022; 3(3): 80-87 [DOI: 10.35712/aig.v3.i3.80] [Reference Citation Analysis]
13 Monserrat-mesquida M, Quetglas-llabrés M, Bouzas C, Montemayor S, Mascaró CM, Casares M, Llompart I, Gámez JM, Tejada S, Martínez JA, Tur JA, Sureda A. A Greater Improvement of Intrahepatic Fat Contents after 6 Months of Lifestyle Intervention Is Related to a Better Oxidative Stress and Inflammatory Status in Non-Alcoholic Fatty Liver Disease. Antioxidants 2022;11:1266. [DOI: 10.3390/antiox11071266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Attia IM. Log-Linear Model and Multistate Model to Assess the Rate of Fibrosis in Patients With NAFLD. Front Appl Math Stat 2022;8:899247. [DOI: 10.3389/fams.2022.899247] [Reference Citation Analysis]
15 Zeng Y, Cao R, Tao Z, Gao Y. Association between the severity of metabolic dysfunction-associated fatty liver disease and the risk of colorectal neoplasm: a systematic review and meta-analysis. Lipids Health Dis 2022;21:52. [PMID: 35668493 DOI: 10.1186/s12944-022-01659-1] [Reference Citation Analysis]
16 Cho K, Park S, Koyanagi A, Jacob L, Yon DK, Lee SW, Kim MS, Kim SU, Kim BK, Shin JI, Smith L. The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: An umbrella review of meta-analyses of randomized controlled trials. Obes Rev 2022;:e13464. [PMID: 35582982 DOI: 10.1111/obr.13464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Zhou H, Zeng X, Xue Y, Wang X, Liu S, Zhu Z, Luo Z, Ma Z, Zhang H, Zhan Q, Bai Y, Huang X, Zeng Q, Ren H, Xu D. Visit-to-Visit Fasting Glucose Variability in Young Adulthood and Nonalcoholic Fatty Liver Disease in Middle Age. J Clin Endocrinol Metab 2022;107:e2301-8. [PMID: 35244697 DOI: 10.1210/clinem/dgac122] [Reference Citation Analysis]
18 Branković M, Jovanović I, Dukić M, Radonjić T, Oprić S, Klašnja S, Zdravković M. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. Int J Mol Sci 2022;23:5146. [PMID: 35563534 DOI: 10.3390/ijms23095146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Woreta TA, Van Natta ML, Lazo M, Krishnan A, Neuschwander-Tetri BA, Loomba R, Mae Diehl A, Abdelmalek MF, Chalasani N, Gawrieh S, Dasarathy S, Vuppalanchi R, Siddiqui MS, Kowdley KV, McCullough A, Terrault NA, Behling C, Kleiner DE, Fishbein M, Hertel P, Wilson LA, Mitchell EP, Miriel LA, Clark JM, Tonascia J, Sanyal AJ; NASH Clinical Research Network. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS One 2022;17:e0266859. [PMID: 35427375 DOI: 10.1371/journal.pone.0266859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Umemura A, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Potential Therapeutic Targets and Promising Agents for Combating NAFLD. Biomedicines 2022;10:901. [DOI: 10.3390/biomedicines10040901] [Reference Citation Analysis]
21 Miguel FM, Picada JN, da Silva JB, Schemitt EG, Colares JR, Hartmann RM, Marroni CA, Marroni NP. Melatonin Attenuates Inflammation, Oxidative Stress, and DNA Damage in Mice with Nonalcoholic Steatohepatitis Induced by a Methionine- and Choline-Deficient Diet. Inflammation 2022. [PMID: 35419738 DOI: 10.1007/s10753-022-01667-4] [Reference Citation Analysis]
22 Gluvic Z, Tomasevic R, Bojovic K, Obradovic M, Isenovic ER. Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. Emergency and Critical Care Medicine 2022;2:12-22. [DOI: 10.1097/ec9.0000000000000016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Han JE, Shin HB, Ahn YH, Cho HJ, Cheong JY, Park B, Kim SS. Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus. Sci Rep 2022;12:2538. [PMID: 35169195 DOI: 10.1038/s41598-022-06205-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Attia IM. Novel Approach of Multistate Markov Chains to Evaluate Progression in the Expanded Model of Non-alcoholic Fatty Liver Disease. Front Appl Math Stat 2022;7:766085. [DOI: 10.3389/fams.2021.766085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P, Jain AK, Karpen SJ, Lavine JE, Mohammad S, Miriel LA, Molleston JP, Mouzaki M, Sanyal A, Sharkey EP, Schwimmer JB, Tonascia J, Wilson LA, Xanthakos SA; NASH Clinical Research Network. Randomized placebo-controlled trial of losartan for pediatric NAFLD. Hepatology 2022. [PMID: 35133671 DOI: 10.1002/hep.32403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Martinou E, Pericleous M, Stefanova I, Kaur V, Angelidi AM. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics (Basel) 2022;12:407. [PMID: 35204498 DOI: 10.3390/diagnostics12020407] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
27 Segura-Azuara NLÁ, Varela-Chinchilla CD, Trinidad-Calderón PA. MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. Front Med (Lausanne) 2021;8:774079. [PMID: 35096868 DOI: 10.3389/fmed.2021.774079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Huang Z, Ng K, Chen H, Deng W, Li Y. Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement. Front Endocrinol 2022;12:739875. [DOI: 10.3389/fendo.2021.739875] [Reference Citation Analysis]
29 Duseja A, Singh SP, Mehta M, Shalimar, Venkataraman J, Mehta V, Devadas K, Kar SK, Goyal O, Nagral A, Saigal S, Nijhawan S, Praharaj D, Shukla A, Sharma B, Narayanasamy K, Kumar P, Rao PN, Arora A, Mehta R, Asati P, Ranjan P, Koshy A, Alam S, Mukewar S, Mukewar S, Mohan Prasad VG, Rastogi M, Sanyal AJ. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord 2022. [PMID: 35085026 DOI: 10.1089/met.2021.0104] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Xu Z, Shi L, Li D, Wu Q, Zhang Y, Gao M, Ji A, Jiang Q, Chen R, Zhang R, Chen W, Zheng Y, Cui L. Real ambient particulate matter-induced lipid metabolism disorder: Roles of peroxisome proliferators-activated receptor alpha. Ecotoxicol Environ Saf 2022;231:113173. [PMID: 35007830 DOI: 10.1016/j.ecoenv.2022.113173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022;19:60-78. [PMID: 34707258 DOI: 10.1038/s41575-021-00523-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 39.0] [Reference Citation Analysis]
32 Gavril RS, Mitu O, Zota IM, Constantin MML, Mastaleru A, Gavril OI, Vasilcu T, Drugescu A, Arhire LI, Mihalache L, Mitu F. Nonalcoholic Fatty Liver Disease – Cardiovascular Risk Factor in Pacients with Type 2 Diabetes Mellitus. Internal Medicine 2021;18:21-7. [DOI: 10.2478/inmed-2021-0187] [Reference Citation Analysis]
33 Alhinai A, Qayyum-Khan A, Zhang X, Samaha P, Metrakos P, Deschenes M, Wong P, Ghali P, Chen TY, Sebastiani G. Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study. World J Hepatol 2021; 13(12): 2179-2191 [DOI: 10.4254/wjh.v13.i12.2179] [Reference Citation Analysis]
34 Wong MYZ, Yap JJL, Sultana R, Cheah M, Goh GBB, Yeo KK. Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis. Open Heart 2021;8:e001850. [PMID: 34933963 DOI: 10.1136/openhrt-2021-001850] [Reference Citation Analysis]
35 Huang YP, Zhang S, Zhang M, Wang Y, Wang WH, Li J, Li C, Lin JN. Gender-specific prevalence of metabolic-associated fatty liver disease among government employees in Tianjin, China: a cross-sectional study. BMJ Open 2021;11:e056260. [PMID: 34911725 DOI: 10.1136/bmjopen-2021-056260] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Ismaiel A, Jaaouani A, Leucuta DC, Popa SL, Dumitrascu DL. The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis. Biomedicines 2021;9:1890. [PMID: 34944706 DOI: 10.3390/biomedicines9121890] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, Ekstedt M, Esmat G, George J, Marchesini G, Novak K, Ocama P, Ratziu V, Razavi H, Romero-Gómez M, Silva M, Spearman CW, Tacke F, Tsochatzis EA, Yilmaz Y, Younossi ZM, Wong VW, Zelber-Sagi S, Cortez-Pinto H, Anstee QM; NAFLD policy review collaborators. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J Hepatol 2021:S0168-8278(21)02168-1. [PMID: 34895743 DOI: 10.1016/j.jhep.2021.10.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 19.0] [Reference Citation Analysis]
38 Schnegelberger RD, Lang AL, Arteel GE, Beier JI. Environmental toxicant-induced maladaptive mitochondrial changes: A potential unifying mechanism in fatty liver disease? Acta Pharm Sin B 2021;11:3756-67. [PMID: 35024304 DOI: 10.1016/j.apsb.2021.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021; 13(11): 1584-1610 [PMID: 34904031 DOI: 10.4254/wjh.v13.i11.1584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
40 Chung J, Park HS, Kim YJ, Yu MH, Park S, Jung SI. Association of Hepatic Steatosis Index with Nonalcoholic Fatty Liver Disease Diagnosed by Non-Enhanced CT in a Screening Population. Diagnostics (Basel) 2021;11:2168. [PMID: 34943405 DOI: 10.3390/diagnostics11122168] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
41 Gavril OI, Arhire LI, Gavril RS, Zota MI, Gherasim A, Nita O, Drugescu A, Oprescu AC, Esanu IM, Mitu F, Graur M, Mihalache L. Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients. Medicina (Kaunas) 2021;57:1249. [PMID: 34833467 DOI: 10.3390/medicina57111249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Di Mauro S, Scamporrino A, Filippello A, Di Pino A, Scicali R, Malaguarnera R, Purrello F, Piro S. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. Int J Mol Sci 2021;22:11905. [PMID: 34769333 DOI: 10.3390/ijms222111905] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
43 Qi Y, Fan L, Ran D, Xu J, Wang Y, Wu J, Zhang Z. Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Oncol 2021;2021:7764817. [PMID: 34691178 DOI: 10.1155/2021/7764817] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
44 Goldberg RB, Tripputi MT, Boyko EJ, Budoff M, Chen ZZ, Clark JM, Dabelea DM, Edelstein SL, Gerszten RE, Horton E, Mather KJ, Perreault L, Temprosa M, Wallia A, Watson K, Irfan Z. Hepatic Fat in Participants With and Without Incident Diabetes in the Diabetes Prevention Program Outcome Study. J Clin Endocrinol Metab 2021;106:e4746-65. [PMID: 33705543 DOI: 10.1210/clinem/dgab160] [Reference Citation Analysis]
45 Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology 2021;74:1809-24. [PMID: 33811367 DOI: 10.1002/hep.31843] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 39.0] [Reference Citation Analysis]
46 Padda J, Khalid K, Khedr A, Tasnim F, Al-Ewaidat OA, Cooper AC, Jean-Charles G. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus 2021;13:e17321. [PMID: 34557367 DOI: 10.7759/cureus.17321] [Reference Citation Analysis]
47 Riyazuddin M, Shahid A. Non-alcoholic fatty liver disease - discussed under the light of Unani medicine. J Complement Integr Med 2021. [PMID: 34551462 DOI: 10.1515/jcim-2021-0296] [Reference Citation Analysis]
48 Wu MJ, Fang QL, Zou SY, Zhu Y, Lu W, Du X, Shi BM. Influencing factors for hepatic fat accumulation in patients with type 2 diabetes mellitus. World J Clin Cases 2021; 9(26): 7717-7728 [PMID: 34621822 DOI: 10.12998/wjcc.v9.i26.7717] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Neagoe CD, Farmazon AS, Amzolini AM, Singer CE, Ianoşi SL, Tutunaru CV, Genunche-Dumitrescu AV, Ianoşi NG, Păun I, Leru PM, Tica OS, Popescu M. The role of non-invasive scores in determining the liver fibrosis in NAFLD and psoriatic patients. Rom J Morphol Embryol 2020;61:503-11. [PMID: 33544802 DOI: 10.47162/RJME.61.2.20] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
50 Sugimoto K, Lee DH, Lee JY, Yu SJ, Moriyasu F, Sakamaki K, Oshiro H, Takahashi H, Kakegawa T, Tomita Y, Abe M, Yoshimasu Y, Takeuchi H, Choi BI, Itoi T. Multiparametric US for Identifying Patients with High-Risk NASH: A Derivation and Validation Study. Radiology 2021;301:625-34. [PMID: 34519576 DOI: 10.1148/radiol.2021210046] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
51 Hefner M, Baliga V, Amphay K, Ramos D, Hegde V. Cardiometabolic Modification of Amyloid Beta in Alzheimer's Disease Pathology. Front Aging Neurosci 2021;13:721858. [PMID: 34497507 DOI: 10.3389/fnagi.2021.721858] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 2021:gutjnl-2021-325724. [PMID: 34489307 DOI: 10.1136/gutjnl-2021-325724] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
53 Jothimani D, Danielraj S, Narasimhan G, Kaliamoorthy I, Rajakumar A, Palaniappan K, Palanichamy S, Rammohan A, Ramachandran H, Rajalingam R, Rela M. Nonalcoholic Steatohepatitis: A Rapidly Increasing Indication for Liver Transplantation in India. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.09.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Lin YC, Wang HY, Kuo YC, Chen MJ, Wu MS, Liu CJ, Yang HW, Shih SC, Yu LY, Ko HJ, Yeh HI, Hu KC. Gut-flora metabolites is not associated with synchronous carotid artery plaque and non-alcoholic fatty liver disease in asymptomatic adults: A STROBE-compliant article. Medicine (Baltimore) 2021;100:e27048. [PMID: 34449492 DOI: 10.1097/MD.0000000000027048] [Reference Citation Analysis]
55 Goday A, Julià H, de Vargas-Machuca A, Pedro-Botet J, Benavente S, Ramon JM, Pera M, Casajoana A, Villatoro M, Fontané L, Bisbe M, Climent E, Castañer O, Flores Le Roux JA, Benaiges D. Bariatric surgery improves metabolic and nonalcoholic fatty liver disease markers in metabolically healthy patients with morbid obesity at 5 years. Surg Obes Relat Dis 2021:S1550-7289(21)00384-1. [PMID: 34509375 DOI: 10.1016/j.soard.2021.07.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Boursier J, Guillaume M, Bouzbib C, Lannes A, Pais R, Smatti S, Cariou B, Bureau C, Ganne-Carrié N, Bourlière M, de Lédinghen V. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF NON-ALCOHOLIC FATTY LIVER DISEASE. Clin Res Hepatol Gastroenterol 2021;:101769. [PMID: 34332133 DOI: 10.1016/j.clinre.2021.101769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Rodriguez LA, Kanaya AM, Shiboski SC, Fernandez A, Herrington D, Ding J, Bradshaw PT. Does NAFLD mediate the relationship between obesity and type 2 diabetes risk? evidence from the multi-ethnic study of atherosclerosis (MESA). Ann Epidemiol 2021;63:15-21. [PMID: 34293421 DOI: 10.1016/j.annepidem.2021.07.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Reja M, Patel R, Pioppo L, Tawadros A, Bhurwal A, Marino D, Rustgi V. Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic Steatohepatitis. J Clin Gastroenterol 2021;55:433-8. [PMID: 32740097 DOI: 10.1097/MCG.0000000000001389] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Hirono H, Watanabe K, Hasegawa K, Kohno M, Terai S, Ohkoshi S. Impact of continuous positive airway pressure therapy for nonalcoholic fatty liver disease in patients with obstructive sleep apnea. World J Clin Cases 2021; 9(19): 5112-5125 [PMID: 34307562 DOI: 10.12998/wjcc.v9.i19.5112] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Lee CO, Li HL, Tsoi MF, Cheung CL, Cheung BMY. Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999-2016. Ann Med 2021;53:1065-73. [PMID: 34184611 DOI: 10.1080/07853890.2021.1943514] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
61 Van Dijk AM, Vali Y, Mak AL, Lee J, Tushuizen ME, Zafarmand MH, Anstee QM, Brosnan MJ, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:2910. [PMID: 34209858 DOI: 10.3390/jcm10132910] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
62 Lazarus JV, Anstee QM, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis EA, Wong VW, Younossi ZM, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34172937 DOI: 10.1038/s41575-021-00477-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 25.0] [Reference Citation Analysis]
63 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
64 Takae M, Fujisue K, Yamamoto E, Egashira K, Komorita T, Oike F, Nishihara T, Yamamoto M, Hirakawa K, Tabata N, Tokitsu T, Yamanaga K, Sueta D, Hanatani S, Nakamura T, Usuku H, Araki S, Arima Y, Takashio S, Suzuki S, Kaikita K, Matsushita K, Tsujita K. Prognostic significance of liver stiffness assessed by fibrosis-4 index in patients with heart failure. ESC Heart Fail 2021. [PMID: 34156170 DOI: 10.1002/ehf2.13351] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
65 Seen TK, Sayed M, Bilal M, Reyes JV, Bhandari P, Lourdusamy V, Al-khazraji A, Syed U, Sattar Y, Bansal R. Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis. World J Gastroenterol 2021; 27(23): 3238-3248 [PMID: 34163108 DOI: 10.3748/wjg.v27.i23.3238] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
66 Higashiura Y, Furuhashi M, Tanaka M, Takahashi S, Koyama M, Ohnishi H, Numata K, Hisasue T, Hanawa N, Moniwa N, Tsuchihashi K, Miura T. High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects. Sci Rep 2021;11:12830. [PMID: 34145341 DOI: 10.1038/s41598-021-92292-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Papachristodoulou A, Kavvadas D, Karamitsos A, Papamitsou T, Chatzidimitriou M, Sioga A. Diagnosis and Staging of Pediatric Non-Alcoholic Fatty Liver Disease: Is Classical Ultrasound the Answer? Pediatr Rep 2021;13:312-21. [PMID: 34201230 DOI: 10.3390/pediatric13020039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 He T, Zhang X, Hao J, Ding S. Phosphatase and Tensin Homolog in Non-neoplastic Digestive Disease: More Than Just Tumor Suppressor. Front Physiol 2021;12:684529. [PMID: 34140896 DOI: 10.3389/fphys.2021.684529] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
69 Eletreby R, Abdellatif Z, Gaber Y, Ramadan A, Ahmad N, Khattab H, Said M, Saad Y. Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00115-6] [Reference Citation Analysis]
70 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
71 Hama M, Horie R, Kubota T, Matsumura T, Kimura E, Nakamura H, Takahashi MP, Takada H. Metabolic complications in myotonic dystrophy type 1: A cross-sectional survey using the National Registry of Japan. J Neurol Sci 2021;427:117511. [PMID: 34082146 DOI: 10.1016/j.jns.2021.117511] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Kawanaka M, Nishino K, Ishii K, Tanikawa T, Urata N, Suehiro M, Sasai T, Haruma K, Kawamoto H. Combination of type IV collagen 7S, albumin concentrations, and platelet count predicts prognosis of non-alcoholic fatty liver disease. World J Hepatol 2021; 13(5): 571-583 [PMID: 34131471 DOI: 10.4254/wjh.v13.i5.571] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Semmler G, Wernly S, Bachmayer S, Leitner I, Wernly B, Egger M, Schwenoha L, Datz L, Balcar L, Semmler M, Stickel F, Niederseer D, Aigner E, Datz C. Metabolic dysfunction-associated fatty liver disease (MAFLD) - rather a bystander than a driver of mortality. J Clin Endocrinol Metab 2021:dgab339. [PMID: 33982065 DOI: 10.1210/clinem/dgab339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
74 Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 2021;70:962-9. [PMID: 32938692 DOI: 10.1136/gutjnl-2020-322572] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 84.0] [Reference Citation Analysis]
75 Ashraf H, Karbalai S, Jamali R. Nonalcoholic fatty liver disease and cardiovascular concerns: The time for hepatologist and cardiologist close collaboration. WJMA 2021;9:163-74. [DOI: 10.13105/wjma.v9.i2.163] [Reference Citation Analysis]
76 Ashraf H, Karbalai S, Jamali R. Nonalcoholic fatty liver disease and cardiovascular concerns: The time for hepatologist and cardiologist close collaboration. World J Meta-Anal 2021; 9(2): 164-175 [DOI: 10.13105/wjma.v9.i2.164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
77 Belinchón-Romero I, Bellot P, Romero-Pérez D, Herraiz-Romero I, Marco F, Frances R, Ramos-Rincón JM. Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. Sci Rep 2021;11:8593. [PMID: 33883616 DOI: 10.1038/s41598-021-88043-8] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
78 Albhaisi S, Sanyal AJ. Does Nonalcoholic Fatty Liver Disease Increase the Risk for Extrahepatic Malignancies? Clin Liver Dis (Hoboken) 2021;17:215-9. [PMID: 33868668 DOI: 10.1002/cld.1029] [Reference Citation Analysis]
79 Toman D, Vavra P, Jelinek P, Ostruszka P, Ihnat P, Foltys A, Pelikan A, Roman J. Effect of bariatric surgery on fatty liver disease in obese patients: A prospective one year follow-up study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2021. [PMID: 33885048 DOI: 10.5507/bp.2021.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Thong VD, Quynh BTH. Correlation of Serum Transaminase Levels with Liver Fibrosis Assessed by Transient Elastography in Vietnamese Patients with Nonalcoholic Fatty Liver Disease. Int J Gen Med 2021;14:1349-55. [PMID: 33889015 DOI: 10.2147/IJGM.S309311] [Reference Citation Analysis]
81 Roeb E. Non-alcoholic fatty liver diseases: current challenges and future directions. Ann Transl Med 2021;9:726. [PMID: 33987424 DOI: 10.21037/atm-20-3760] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
82 Rosso N, Stephenson AM, Giraudi PJ, Tiribelli C. Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review. Ann Transl Med 2021;9:727. [PMID: 33987425 DOI: 10.21037/atm-20-4723] [Reference Citation Analysis]
83 Schreiner AD, Zhang J, Durkalski-Mauldin V, Livingston S, Marsden J, Bian J, Mauldin PD, Moran WP, Rockey DC. Advanced liver fibrosis and the metabolic syndrome in a primary care setting. Diabetes Metab Res Rev 2021. [PMID: 33759300 DOI: 10.1002/dmrr.3452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 DeBoer MD, Lin B, Filipp SL, Cusi K, Gurka MJ. Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis. Nutr Res 2021;88:34-43. [PMID: 33743323 DOI: 10.1016/j.nutres.2020.12.023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Hempel F, Roderfeld M, Müntnich LJ, Albrecht J, Oruc Z, Arneth B, Karrasch T, Pons-Kühnemann J, Padberg W, Renz H, Schäffler A, Roeb E. Caspase-Cleaved Keratin 18 Measurements Identified Ongoing Liver Injury after Bariatric Surgery. J Clin Med 2021;10:1233. [PMID: 33809676 DOI: 10.3390/jcm10061233] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
86 Kao WY, Lin YF, Chang IW, Chen CL, Tang JH, Chang CC, Chang YJ, Wang W. Interleukin-2 receptor alpha as a biomarker for nonalcoholic fatty liver disease diagnosis. J Chin Med Assoc 2021;84:261-6. [PMID: 33306598 DOI: 10.1097/JCMA.0000000000000469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Sturm L, Roth L, Zoldan K, Schultheiss M, Boettler T, Huber JP, Kaeser R, Thimme R, Bettinger D. Blood reelin in the progression of chronic liver disease. Adv Med Sci 2021;66:148-54. [PMID: 33561810 DOI: 10.1016/j.advms.2021.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 De Vincentis A, Antonelli-Incalzi R, Picardi A, Vespasiani-Gentilucci U. Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient. J Diabetes Complications 2021;35:107891. [PMID: 33642147 DOI: 10.1016/j.jdiacomp.2021.107891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Jensen VS, Fledelius C, Zachodnik C, Damgaard J, Nygaard H, Tornqvist KS, Kirk RK, Viuff BM, Wulff EM, Lykkesfeldt J, Hvid H. Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD. J Transl Med 2021;19:80. [PMID: 33596938 DOI: 10.1186/s12967-021-02729-1] [Reference Citation Analysis]
90 Stahlschmidt FL, Tafarel JR, Menini-Stahlschmidt CM, Baena CP. Hepatorenal index for grading liver steatosis with concomitant fibrosis. PLoS One 2021;16:e0246837. [PMID: 33577616 DOI: 10.1371/journal.pone.0246837] [Reference Citation Analysis]
91 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
92 Campbell P, Symonds A, Barritt AS 4th. Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions. Clin Ther 2021;43:500-17. [PMID: 33583577 DOI: 10.1016/j.clinthera.2021.01.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
93 Kogachi S, Noureddin M. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Ther 2021;43:455-72. [PMID: 33581876 DOI: 10.1016/j.clinthera.2021.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
94 Iruzubieta P, Arias-Loste MT, Fortea JI, Cuadrado A, Rivas-Rivas C, Rodriguez-Duque JC, García-Ibarbia C, Hernández JL, Crespo J. National digestive disease specialists survey on cardiovascular risk management in non-alcoholic fatty liver disease in spanish hospitals. Liver Int 2021;41:1243-53. [PMID: 33527637 DOI: 10.1111/liv.14807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. Curr Pharm Des 2020;26:3928-38. [PMID: 32436818 DOI: 10.2174/1381612826666200521133307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Oza N, Hyogo H, Ono M, Kawaguchi T, Torimura T, Anzai K, Eguchi Y, Takahashi H. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics (Basel) 2021;11:132. [PMID: 33467114 DOI: 10.3390/diagnostics11010132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
97 Palmieri B, Corazzari V, Panariello Brasile DG, Sangiovanni V, VadalÀ M. Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration. Minerva Gastroenterol Dietol 2020;66:307-20. [PMID: 33443240 DOI: 10.23736/S1121-421X.20.02738-5] [Reference Citation Analysis]
98 Lin Y, Gong X, Li X, Shao C, Wu T, Li M, Li F, Ma Q, Ye J, Zhong B. Distinct Cause of Death Profiles of Hospitalized Non-alcoholic Fatty Liver Disease: A 10 Years' Cross-Sectional Multicenter Study in China. Front Med (Lausanne) 2020;7:584396. [PMID: 33511140 DOI: 10.3389/fmed.2020.584396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
99 Chiriac S, Stanciu C, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Cuciureanu T, Huiban L, Muzica CM, Zenovia S, Nastasa R, Trifan A. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Can J Gastroenterol Hepatol 2021;2021:6696857. [PMID: 33505944 DOI: 10.1155/2021/6696857] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
100 Ciardullo S, Muraca E, Perra S, Bianconi E, Zerbini F, Oltolini A, Cannistraci R, Parmeggiani P, Manzoni G, Gastaldelli A, Lattuada G, Perseghin G. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Res Care. 2020;8. [PMID: 32049637 DOI: 10.1136/bmjdrc-2019-000904] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 40.0] [Reference Citation Analysis]
101 Kosick HM, Keyrouz A, Adeyi O, Sebastiani G, Patel K. A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 33389416 DOI: 10.1007/s10620-020-06748-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 He Y, Jiang J, He B, Shi Z. Chemical Activators of the Nrf2 Signaling Pathway in Nonalcoholic Fatty Liver Disease. Natural Product Communications 2021;16:1934578X2098709. [DOI: 10.1177/1934578x20987095] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Wen F, Shi Z, Liu X, Tan Y, Wei L, Zhu X, Zhang H, Zhu X, Meng X, Ji W, Yang M, Lu Z. Acute Elevated Resistin Exacerbates Mitochondrial Damage and Aggravates Liver Steatosis Through AMPK/PGC-1α Signaling Pathway in Male NAFLD Mice. Horm Metab Res 2021;53:132-44. [PMID: 33302316 DOI: 10.1055/a-1293-8250] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
104 Michel M, Schattenberg JM. [Liver-specific diagnostic for non-alcoholic fatty liver disease (NAFLD) - time to replace liver biopsy?]. Z Gastroenterol 2020;58:1233-40. [PMID: 33291177 DOI: 10.1055/a-1291-8483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
105 Park H, Jun DW, Park HK, Kim M. Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes. Ann Transl Med 2020;8:1583. [PMID: 33437782 DOI: 10.21037/atm-20-5216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Zhao H, Yang A, Mao L, Quan Y, Cui J, Sun Y. Association Between Dietary Fiber Intake and Non-alcoholic Fatty Liver Disease in Adults. Front Nutr 2020;7:593735. [PMID: 33330594 DOI: 10.3389/fnut.2020.593735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
107 Kuchay MS, Choudhary NS, Mishra SK, Misra A. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes. Diabetes Metab Syndr 2020;14:2233-9. [PMID: 33336648 DOI: 10.1016/j.dsx.2020.11.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
108 Spinosa M, Stine JG. Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State? Curr Pharm Des 2020;26:1036-44. [PMID: 32003679 DOI: 10.2174/1381612826666200131101553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
109 Kage M, Aishima S, Kusano H, Yano H. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Med Ultrason (2001) 2020;47:549-54. [PMID: 33136250 DOI: 10.1007/s10396-020-01061-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
110 Maev IV, Samsonov AA, Lazebnik LB, Golovanova EV, Pavlov CS, Vovk EI, Ratziu V, Starostin KM. A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. Adv Ther 2020;37:4627-40. [PMID: 32939691 DOI: 10.1007/s12325-020-01493-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Vieira Barbosa J, Lai M. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. Hepatol Commun 2021;5:158-67. [PMID: 33553966 DOI: 10.1002/hep4.1618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
112 Mann JP, Carter P, Armstrong MJ, Abdelaziz HK, Uppal H, Patel B, Chandran S, More R, Newsome PN, Potluri R. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors. PLoS One. 2020;15:e0241357. [PMID: 33108366 DOI: 10.1371/journal.pone.0241357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Mohammed ED, Abdel-Naim AB, Kangpeng J, Jiang R, Wei J, Sun B. The mother relationship between insulin resistance and non-alcoholic steatohepatitis: Glucosinolates hydrolysis products as a promising insulin resistance-modulator and fatty liver-preventer. Life Sci 2021;264:118615. [PMID: 33096115 DOI: 10.1016/j.lfs.2020.118615] [Reference Citation Analysis]
114 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
115 Samejo SA, Abbas Z, Asim M. Effects of anthropometric and metabolic parameters on transaminase levels and liver stiffness in patients with non-alcohol fatty liver disease. Trop Doct 2021;51:185-9. [PMID: 33040692 DOI: 10.1177/0049475520962742] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Wijarnpreecha K, Kim D, Raymond P, Scribani M, Ahmed A. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. Eur J Gastroenterol Hepatol 2019;31:1121-8. [PMID: 30888971 DOI: 10.1097/MEG.0000000000001397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 8.5] [Reference Citation Analysis]
117 Zhang S, Wong YT, Tang KY, Kwan HY, Su T. Chinese Medicinal Herbs Targeting the Gut-Liver Axis and Adipose Tissue-Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science. Front Endocrinol (Lausanne) 2020;11:572729. [PMID: 33101207 DOI: 10.3389/fendo.2020.572729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
118 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Moret A, Boursier J, Houssel Debry P, Riou J, Crouan A, Dubois M, Michalak Provost S, Aubé C, Paisant A. Evaluation of the Hepatorenal B-Mode Ratio and the "Controlled Attenuation Parameter" for the Detection and Grading of Steatosis. Ultraschall Med 2020. [PMID: 32992377 DOI: 10.1055/a-1233-2290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
120 Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Curr Vasc Pharmacol 2020;18:172-81. [PMID: 30961499 DOI: 10.2174/1570161117666190405164313] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
121 Hydes T, Buchanan R, Kennedy OJ, Fraser S, Parkes J, Roderick P. Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease. BMJ Open 2020;10:e040970. [PMID: 32988952 DOI: 10.1136/bmjopen-2020-040970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
122 Fujita T, Daimon M, Mizushiri S, Nishiya Y, Murakami H, Tanabe J, Matsuhashi Y, Yanagimachi M, Tokuda I, Sawada K, Ihara K. FIB-4 index is a marker for a subsequent decrease in insulin secretion in a non-diabetic Japanese population. Sci Rep 2020;10:15814. [PMID: 32978491 DOI: 10.1038/s41598-020-72894-8] [Reference Citation Analysis]
123 Rosato V, Masarone M, Aglitti A, Persico M. The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Stefano JT, Guedes LV, de Souza AAA, Vanni DS, Alves VAF, Carrilho FJ, Largura A, Arrese M, Oliveira CP. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. Ann Hepatol 2021;20:100253. [PMID: 32949785 DOI: 10.1016/j.aohep.2020.08.070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
125 Muyyarikkandy MS, McLeod M, Maguire M, Mahar R, Kattapuram N, Zhang C, Surugihalli C, Muralidaran V, Vavilikolanu K, Mathews CE, Merritt ME, Sunny NE. Branched chain amino acids and carbohydrate restriction exacerbate ketogenesis and hepatic mitochondrial oxidative dysfunction during NAFLD. FASEB J 2020;34:14832-49. [PMID: 32918763 DOI: 10.1096/fj.202001495R] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
126 Lee J, Vali Y, Boursier J, Duffin K, Verheij J, Brosnan MJ, Zwinderman K, Anstee QM, Bossuyt PM, Zafarmand MH. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLoS One 2020;15:e0238717. [PMID: 32915852 DOI: 10.1371/journal.pone.0238717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
127 Acierno C, Caturano A, Pafundi PC, Nevola R, Adinolfi LE, Sasso FC. Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
128 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
129 Mikolasevic I, Lukic A, Juric T, Klapan M, Madzar P, Krolo N, Kolovrat D, Jurica I, Kedmenec I, Kihas D, Ilovaca D, Erstic I, Haralovic V, Cavlina D, Dejhalla E, Erdeljac D, Vukalovic B, Skenderevic N, Milic S. Non-alcoholic fatty liver disease and transient elastography. Exploration of Medicine 2020;1:205-17. [DOI: 10.37349/emed.2020.00014] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
130 Tincopa MA. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00177. [PMID: 33102798 DOI: 10.1002/edm2.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
131 Acín S, Muñoz DL, Guillen A, Soscue D, Castaño A, Echeverri F, Balcazar N. Triterpene-enriched fractions from Eucalyptus tereticornis ameliorate metabolic alterations in a mouse model of diet-induced obesity. J Ethnopharmacol 2021;265:113298. [PMID: 32860892 DOI: 10.1016/j.jep.2020.113298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Liebig S, Stoeckmann N, Geier A, Rau M, Schattenberg JM, Bahr MJ, Manns MP, Jaeckel E, Schulze-Osthoff K, Bantel H. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness. Clin Transl Gastroenterol 2019;10:e00066. [PMID: 31397685 DOI: 10.14309/ctg.0000000000000066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
133 Solfrizzi V, Scafato E, Custodero C, Loparco F, Ciavarella A, Panza F, Seripa D, Imbimbo BP, Lozupone M, Napoli N, Piazzolla G, Galluzzo L, Gandin C, Baldereschi M, Di Carlo A, Inzitari D, Pilotto A, Sabbà C; Italian Longitudinal Study on Aging Working Group. Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. Alzheimers Dement (N Y) 2020;6:e12065. [PMID: 32864415 DOI: 10.1002/trc2.12065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
134 Zhang X, Deng Y, Xiang J, Liu H, Zhang J, Liao J, Chen K, Liu B, Liu J, Pu Y. Galangin Improved Non-Alcoholic Fatty Liver Disease in Mice by Promoting Autophagy. Drug Des Devel Ther 2020;14:3393-405. [PMID: 32884242 DOI: 10.2147/DDDT.S258187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
135 Monserrat-Mesquida M, Quetglas-Llabrés M, Abbate M, Montemayor S, Mascaró CM, Casares M, Tejada S, Abete I, Zulet MA, Tur JA, Martínez JA, Sureda A. Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel) 2020;9:E759. [PMID: 32824349 DOI: 10.3390/antiox9080759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
136 Im HJ, Hwang SJ, Lee JS, Lee SB, Kang JY, Son CG. Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model. Nutrients 2020;12:E2433. [PMID: 32823613 DOI: 10.3390/nu12082433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
137 Masaki S, Hashimoto Y, Kunisho S, Kimoto A, Kitadai Y. Fatty change of the liver microenvironment influences the metastatic potential of colorectal cancer. Int J Exp Pathol 2020;101:162-70. [PMID: 32783302 DOI: 10.1111/iep.12371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
138 Desai SM, Sanap AP, Bhonde RR. Treat liver to beat diabetes. Med Hypotheses 2020;144:110034. [PMID: 32758878 DOI: 10.1016/j.mehy.2020.110034] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
139 Muthiah MD, Sanyal AJ. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:1-23. [PMID: 32033757 DOI: 10.1016/j.gtc.2019.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
140 Cunningham RP, Sheldon RD, Rector RS. The Emerging Role of Hepatocellular eNOS in Non-alcoholic Fatty Liver Disease Development. Front Physiol 2020;11:767. [PMID: 32719616 DOI: 10.3389/fphys.2020.00767] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
141 Vo HD, Harp KA, Mauch TJ. Diagnostic performance of non-invasive tests for evaluation of hepatic graft fibrosis in pediatric liver transplantation: A scoping review. Transplant Rev (Orlando) 2020;34:100568. [PMID: 32713759 DOI: 10.1016/j.trre.2020.100568] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
142 Lee AK, Kim DH, Bang E, Choi YJ, Chung HY. β-Hydroxybutyrate Suppresses Lipid Accumulation in Aged Liver through GPR109A-mediated Signaling. Aging Dis 2020;11:777-90. [PMID: 32765945 DOI: 10.14336/AD.2019.0926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
143 Xanthakos SA, Lavine JE, Yates KP, Schwimmer JB, Molleston JP, Rosenthal P, Murray KF, Vos MB, Jain AK, Scheimann AO, Miloh T, Fishbein M, Behling CA, Brunt EM, Sanyal AJ, Tonascia J; NASH Clinical Research Network. Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. Gastroenterology 2020;159:1731-1751.e10. [PMID: 32712103 DOI: 10.1053/j.gastro.2020.07.034] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
144 Kim KB, Kim GH, Song DH, Park HJ, Kim CW. Automatic segmentation of liver/kidney area with double-layered fuzzy C-means and the utility of hepatorenal index for fatty liver severity classification. IFS 2020;39:925-36. [DOI: 10.3233/jifs-191850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
145 Le L, Kullar R, Saleh HM, Saab S. Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis. Dig Dis Sci 2020;65:3719-25. [PMID: 32671584 DOI: 10.1007/s10620-020-06382-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
146 Dutra JDM, Lisboa QC, Ferolla SM, Carvalho CMML, Mendes CCM, Ferrari TCA, Couto CA. Vitamin D levels are not associated with non-alcoholic fatty liver disease severity in a Brazilian population. Int J Vitam Nutr Res 2020;:1-8. [PMID: 32639223 DOI: 10.1024/0300-9831/a000667] [Reference Citation Analysis]
147 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
148 Oancea CN, Butaru AE, Streba CT, Pirici D, Rogoveanu I, Diculescu MM, Gheonea DI. Global hepatitis C elimination: history, evolution, revolutionary changes and barriers to overcome. Rom J Morphol Embryol 2021;61:643-53. [DOI: 10.47162/rjme.61.3.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
149 Bertol FS, Araujo B, Jorge BB, Rinaldi N, De Carli LA, Tovo CV. Role of micronutrients in staging of nonalcoholic fatty liver disease: A retrospective cross-sectional study. World J Gastrointest Surg 2020; 12(6): 269-276 [PMID: 32774765 DOI: 10.4240/wjgs.v12.i6.269] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Ekta, Gupta M, Kaur A, Singh TG, Bedi O. Pathobiological and molecular connections involved in the high fructose and high fat diet induced diabetes associated nonalcoholic fatty liver disease. Inflamm Res 2020;69:851-67. [DOI: 10.1007/s00011-020-01373-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
151 Xin S, Zhan Q, Chen X, Xu J, Yu Y. Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis. BMC Gastroenterol 2020;20:186. [PMID: 32532204 DOI: 10.1186/s12876-020-01334-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
152 Asada F, Nomura T, Hosui A, Kubota M. Influence of increased physical activity without body weight loss on hepatic inflammation in patients with nonalcoholic fatty liver disease. Environ Health Prev Med 2020;25:18. [PMID: 32522147 DOI: 10.1186/s12199-020-00857-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
153 Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Curr Vasc Pharmacol 2019;17:498-514. [PMID: 31060488 DOI: 10.2174/1570161117666190507110519] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
154 Shaheen AA, Riazi K, Medellin A, Bhayana D, Kaplan GG, Jiang J, Park R, Schaufert W, Burak KW, Sargious M, Swain MG. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 2020;8:E370-6. [PMID: 32414883 DOI: 10.9778/cmajo.20200009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
155 Emamat H, Ghalandari H, Tangestani H, Abdollahi A, Hekmatdoost A. Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism. EXCLI J 2020;19:620-6. [PMID: 32483408 DOI: 10.17179/excli2020-1226] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
156 Fujii Y, Nouso K, Matsushita H, Kariyama K, Sakurai T, Takahashi Y, Chiba H, Hui S, Ito Y, Ohta M, Okada H. Low-Density Lipoprotein (LDL)-Triglyceride and Its Ratio to LDL-Cholesterol as Diagnostic Biomarkers for Nonalcoholic Steatohepatitis. The Journal of Applied Laboratory Medicine 2020;5:1206-15. [DOI: 10.1093/jalm/jfaa044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Horn P, Newsome PN. Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis? Aliment Pharmacol Ther 2020;51:987-8. [PMID: 32338785 DOI: 10.1111/apt.15682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019;40:1367-1393. [PMID: 31098621 DOI: 10.1210/er.2019-00034] [Cited by in Crossref: 66] [Cited by in F6Publishing: 160] [Article Influence: 33.0] [Reference Citation Analysis]
159 Isaacson RH, Beier JI, Khoo NK, Freeman BA, Freyberg Z, Arteel GE. Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane. J Nutr Biochem 2020;81:108399. [PMID: 32388251 DOI: 10.1016/j.jnutbio.2020.108399] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
160 Hernandez Roman J, Siddiqui MS. The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020;3:e00127. [PMID: 33102796 DOI: 10.1002/edm2.127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
161 Maiwall R, Gupta M. Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation. Transl Gastroenterol Hepatol 2020;5:18. [PMID: 32258522 DOI: 10.21037/tgh.2019.10.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 van Eekelen E, Beulens JWJ, Geelen A, Schrauwen-Hinderling VB, Lamb H, de Roos A, Rosendaal F, de Mutsert R. Consumption of Alcoholic and Sugar-Sweetened Beverages is Associated with Increased Liver Fat Content in Middle-Aged Men and Women. J Nutr 2019;149:649-58. [PMID: 30949667 DOI: 10.1093/jn/nxy313] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
163 Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA 2020;323:1175-83. [PMID: 32207804 DOI: 10.1001/jama.2020.2298] [Cited by in Crossref: 267] [Cited by in F6Publishing: 275] [Article Influence: 133.5] [Reference Citation Analysis]
164 Avramovski P, Avramovska M, Nikleski Z, Ilkovska B, Sotiroski K, Sikole E. The predictive value of the hepatorenal index for detection of impaired glucose metabolism in patients with non-alcoholic fatty liver disease. Indian J Gastroenterol 2020;39:50-9. [PMID: 32185691 DOI: 10.1007/s12664-019-01009-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
165 Meneses D, Olveira A, Corripio R, del Carmen Méndez M, Romero M, Calvo-viñuelas I, Herranz L, Vicent D, de-Cos-Blanco AI. Performance of Noninvasive Liver Fibrosis Scores in the Morbid Obese Patient, Same Scores but Different Thresholds. OBES SURG 2020;30:2538-46. [DOI: 10.1007/s11695-020-04509-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
166 Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. J Intern Med 2020;287:711-22. [DOI: 10.1111/joim.13035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
167 Chang Y, Noh JW, Cheon JY, Kim Y, Kwon YD, Ryu S. Self-rated health and risk of incident non-alcoholic fatty liver disease: A cohort study. Sci Rep 2020;10:3826. [PMID: 32123241 DOI: 10.1038/s41598-020-60823-8] [Reference Citation Analysis]
168 de Carli MA, de Carli LA, Correa MB, Junqueira G, Tovo CV, Coral GP. Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2020;32:420-5. [DOI: 10.1097/meg.0000000000001519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
169 Campbell PT, VanWagner LB, Colangelo LA, Lewis CE, Henkel A, Ajmera VH, Lloyd-Jones DM, Vaughan DE, Khan SS. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA. Liver Int 2020;40:1111-20. [PMID: 32090434 DOI: 10.1111/liv.14417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
170 El-Aziz RA, Alnaggar ARLR, Mohamed Nabih MI, Ali SM, Khattab H, El-Atty SA. Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study. Clin Exp Hepatol 2020;6:28-34. [PMID: 32166121 DOI: 10.5114/ceh.2020.93053] [Reference Citation Analysis]
171 Altaf B, Rehman A, Jawed S, Raouf A. Association of liver biomarkers and cytokeratin-18 in Nonalcoholic fatty liver disease patients. Pak J Med Sci 2020;36:387-90. [PMID: 32292439 DOI: 10.12669/pjms.36.3.1674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
172 Góralska J, Raźny U, Polus A, Dziewońska A, Gruca A, Zdzienicka A, Dembińska-Kieć A, Solnica B, Micek A, Kapusta M, Słowińska-Solnica K, Malczewska-Malec M. Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis. Nutrients 2020;12:E476. [PMID: 32069846 DOI: 10.3390/nu12020476] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
173 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 266] [Article Influence: 60.0] [Reference Citation Analysis]
174 Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;51:728-36. [PMID: 32043602 DOI: 10.1111/apt.15660] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 29.0] [Reference Citation Analysis]
175 Lee DH, Park SH, Huh YH, Jung Kim M, Seo HD, Ha TY, Ahn J, Jang YJ, Jung CH. Iridoids of Valeriana fauriei contribute to alleviating hepatic steatosis in obese mice by lipophagy. Biomed Pharmacother 2020;125:109950. [PMID: 32058217 DOI: 10.1016/j.biopha.2020.109950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
176 DeLegge MH. Recruitment and Retention of Patients for Nonalcoholic Steatohepatitis Clinical Trials. Gastroenterol Clin North Am 2020;49:123-40. [PMID: 32033759 DOI: 10.1016/j.gtc.2019.09.006] [Reference Citation Analysis]
177 Musolino V, Gliozzi M, Bombardelli E, Nucera S, Carresi C, Maiuolo J, Mollace R, Paone S, Bosco F, Scarano F, Scicchitano M, Macrì R, Ruga S, Zito MC, Palma E, Gratteri S, Ragusa M, Volterrani M, Fini M, Mollace V. The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease. J Tradit Complement Med 2020;10:268-74. [PMID: 32670822 DOI: 10.1016/j.jtcme.2020.02.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
178 Miya A, Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study. J Diabetes Investig 2020;11:964-70. [PMID: 31999890 DOI: 10.1111/jdi.13221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
179 Han K, Kwon O, Park HJ, Jung SY, Yang C, Son CG. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial. Trials 2020;21:128. [PMID: 32005283 DOI: 10.1186/s13063-020-4068-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
180 Schuster-Gaul S, Geisler LJ, McGeough MD, Johnson CD, Zagorska A, Li L, Wree A, Barry V, Mikaelian I, Jih LJ, Papouchado BG, Budas G, Hoffman HM, Feldstein AE. ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model. JCI Insight 2020;5:123294. [PMID: 31996485 DOI: 10.1172/jci.insight.123294] [Cited by in Crossref: 15] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
181 Kumar R, Porwal YC, Dev N, Kumar P, Chakravarthy S, Kumawat A. Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian Indians: A cross-sectional study. J Family Med Prim Care 2020;9:390-4. [PMID: 32110624 DOI: 10.4103/jfmpc.jfmpc_887_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
182 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 33.5] [Reference Citation Analysis]
183 Musso G, Saba F, Cassader M, Paschetta E, De Michieli F, Pinach S, Framarin L, Berrutti M, Leone N, Parente R, Ayoubi Khajekini MT, Zarovska A, Gambino R. Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation. Am J Gastroenterol 2019;114:607-19. [PMID: 30920415 DOI: 10.14309/ajg.0000000000000154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
184 Cheung A, Figueredo C, Rinella ME. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol 2019;114:579-90. [PMID: 30839326 DOI: 10.14309/ajg.0000000000000058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
185 Chyau CC, Wang HF, Zhang WJ, Chen CC, Huang SH, Chang CC, Peng RY. Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway. Int J Mol Sci 2020;21:E360. [PMID: 31935815 DOI: 10.3390/ijms21010360] [Cited by in Crossref: 14] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
186 Chang Y, Cho J, Cho YK, Cho A, Hong YS, Zhao D, Ahn J, Sohn CI, Shin H, Guallar E, Ryu S. Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases. Clinical Gastroenterology and Hepatology 2020;18:205-215.e7. [DOI: 10.1016/j.cgh.2019.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
187 Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol 2020;8:76-86. [PMID: 32274348 DOI: 10.14218/JCTH.2019.00051] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
188 Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, Shin H, Ryu S. Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. Am J Gastroenterol. 2019;114:453-463. [PMID: 30353055 DOI: 10.1038/s41395-018-0283-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 45] [Article Influence: 8.7] [Reference Citation Analysis]
189 Alswat KA, Fallatah HI, Al-Judaibi B, Elsiesy HA, Al-Hamoudi WK, Qutub AN, Alturaify N, Al-Osaimi A. Position statement on the diagnosis and management of non-alcoholic fatty liver disease. Saudi Med J 2019;40:531-40. [PMID: 31219486 DOI: 10.15537/smj.2019.6.23980] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
190 Zhang P, Feng W, Chu X, Sun X, Zhu D, Bi Y. A newly noninvasive model for prediction of non-alcoholic fatty liver disease: utility of serum prolactin levels. BMC Gastroenterol 2019;19:202. [PMID: 31775658 DOI: 10.1186/s12876-019-1120-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
191 Akinkugbe AA, Barritt AS, Cai J, Offenbacher S, Thyagarajan B, Khambaty T, Singer R, Kallwitz E, Heiss G, Slade GD. Periodontitis and prevalence of elevated aminotransferases in the Hispanic Community Health Study/Study of Latinos. J Periodontol 2018;89:949-58. [PMID: 29717494 DOI: 10.1002/JPER.17-0579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
192 Chuah K, Chan W. Quantification of Liver Fat in NAFLD: Available Modalities and Clinical Significance. Curr Hepatology Rep 2019;18:492-502. [DOI: 10.1007/s11901-019-00493-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
193 Perakakis N, Polyzos SA, Yazdani A, Sala-Vila A, Kountouras J, Anastasilakis AD, Mantzoros CS. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism 2019;101:154005. [PMID: 31711876 DOI: 10.1016/j.metabol.2019.154005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 18.0] [Reference Citation Analysis]
194 Chan W, Treeprasertsuk S, Goh GB, Fan J, Song MJ, Charatcharoenwitthaya P, Duseja A, Dan Y, Imajo K, Nakajima A, Ho K, Goh K, Wong VW. Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. Clinical Gastroenterology and Hepatology 2019;17:2570-2580.e37. [DOI: 10.1016/j.cgh.2019.03.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 15.0] [Reference Citation Analysis]
195 Mansour A, Mohajeri-Tehrani MR, Samadi M, Gerami H, Qorbani M, Bellissimo N, Poustchi H, Hekmatdoost A. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients. Acta Diabetol 2019;56:1199-207. [PMID: 31197470 DOI: 10.1007/s00592-019-01374-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
196 Jayaraman T, Lee YY, Chan WK, Mahadeva S. Epidemiological differences of common liver conditions between Asia and the West. JGH Open. 2020;4:332-339. [PMID: 32514433 DOI: 10.1002/jgh3.12275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
197 Yousaf MN, Chaudhary FS, Mehal WZ. The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). GHOA 2019;10:262-6. [DOI: 10.15406/ghoa.2019.10.00392] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
198 Lee C, Kim J, Jung Y. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Cells 2019;8:E1259. [PMID: 31619023 DOI: 10.3390/cells8101259] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
199 Lee YS, Lee HS, Chang SW, Lee CU, Kim JS, Jung YK, Kim JH, Seo YS, Yim HJ, Lee CH, Woo SU, Seo JH, Yeon JE, Um SH, Byun KS. Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery. Medicine (Baltimore) 2019;98:e17277. [PMID: 31574842 DOI: 10.1097/MD.0000000000017277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
200 Alam S, Jahid Hasan M, Khan MAS, Alam M, Hasan N. Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient. J Transl Int Med 2019;7:106-14. [PMID: 31637181 DOI: 10.2478/jtim-2019-0023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
201 Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Dhalwani NN, Kendrick S, Celis-Morales C, Waterworth DM, Alazawi W, Sattar N. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019;367:l5367. [PMID: 31594780 DOI: 10.1136/bmj.l5367] [Cited by in Crossref: 68] [Cited by in F6Publishing: 98] [Article Influence: 22.7] [Reference Citation Analysis]
202 Kutaiba N, Rotella JA, Ardalan Z, Testro A. Incidental hepatic steatosis in radiology reports: a survey of emergency department clinicians' perspectives and current practice. J Med Imaging Radiat Oncol 2019;63:573-9. [PMID: 31385415 DOI: 10.1111/1754-9485.12938] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
203 Taylor AC, Maddirela D, White SB. Role of Radioembolization for Biliary Tract and Primary Liver Cancer. Surgical Oncology Clinics of North America 2019;28:731-43. [DOI: 10.1016/j.soc.2019.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
204 Kelly N, Wattacheril J. Nonalcoholic Fatty Liver Disease: Evidence-Based Management and Early Recognition of Nonalcoholic Steatohepatitis. The Journal for Nurse Practitioners 2019;15:622-6. [DOI: 10.1016/j.nurpra.2019.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
205 Singh SP, Barik RK. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet? J Clin Exp Hepatol 2020;10:88-98. [PMID: 32025168 DOI: 10.1016/j.jceh.2019.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
206 De A, Duseja A. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. J Clin Exp Hepatol 2020;10:255-62. [PMID: 32405182 DOI: 10.1016/j.jceh.2019.09.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
207 Ismaiel A, Dumitraşcu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne) 2019;6:202. [PMID: 31616668 DOI: 10.3389/fmed.2019.00202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
208 Khoo S, Wong VW, Goh GB, Fan J, Chan WK, Seto WK, Chow WC. Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2020;35:320-5. [PMID: 31336392 DOI: 10.1111/jgh.14794] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
209 Zuo Y, Sarkar S, Corwin MT, Olson K, Badawi RD, Wang G. Structural and practical identifiability of dual-input kinetic modeling in dynamic PET of liver inflammation. Phys Med Biol 2019;64:175023. [PMID: 31051490 DOI: 10.1088/1361-6560/ab1f29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
210 Dallio M, Diano N, Masarone M, Gravina AG, Patanè V, Romeo M, Di Sarno R, Errico S, Nicolucci C, Abenavoli L, Scarpellini E, Boccuto L, Persico M, Loguercio C, Federico A. Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. Int J Environ Res Public Health 2019;16:E3134. [PMID: 31466361 DOI: 10.3390/ijerph16173134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
211 Liang Y, Liang S, Zhang Y, Deng Y, He Y, Chen Y, Liu C, Lin C, Yang Q. Oral Administration of Compound Probiotics Ameliorates HFD-Induced Gut Microbe Dysbiosis and Chronic Metabolic Inflammation via the G Protein-Coupled Receptor 43 in Non-alcoholic Fatty Liver Disease Rats. Probiotics Antimicrob Proteins. 2019;11:175-185. [PMID: 29353414 DOI: 10.1007/s12602-017-9378-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 53] [Article Influence: 12.7] [Reference Citation Analysis]
212 Issa D, Patel V, Sanyal AJ. Future therapy for non-alcoholic fatty liver disease. Liver Int 2018;38 Suppl 1:56-63. [PMID: 29427492 DOI: 10.1111/liv.13676] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
213 Rajput R, Ahlawat P. Prevalence and predictors of non-alcoholic fatty liver disease in prediabetes. Diabetes Metab Syndr 2019;13:2957-60. [PMID: 31425963 DOI: 10.1016/j.dsx.2019.07.060] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
214 Tariq R, Axley P, Singal AK. Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review. J Clin Exp Hepatol 2020;10:81-7. [PMID: 32025167 DOI: 10.1016/j.jceh.2019.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
215 Kim HN, Joo EJ, Cheong HS, Kim Y, Kim HL, Shin H, Chang Y, Ryu S. Gut Microbiota and Risk of Persistent Nonalcoholic Fatty Liver Diseases. J Clin Med 2019;8:E1089. [PMID: 31344854 DOI: 10.3390/jcm8081089] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
216 Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, Oliveira CP, Govaere O, Younes R, McPherson S, Bedossa P, Nielsen MJ, Karsdal M, Leeming D, Kendrick S, Anstee QM. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep 2019;1:188-98. [PMID: 32039369 DOI: 10.1016/j.jhepr.2019.06.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 18.3] [Reference Citation Analysis]
217 Olubamwo OO, Virtanen JK, Pihlajamaki J, Tuomainen TP. Association of fatty liver index with risk of incident type 2 diabetes by metabolic syndrome status in an Eastern Finland male cohort: a prospective study. BMJ Open 2019;9:e026949. [PMID: 31278098 DOI: 10.1136/bmjopen-2018-026949] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
218 Susutlertpanya W, Wakuda H, Otani N, Kuramoto T, Li L, Kuranari M, Sekiguchi A, Kudo H, Uchida T, Imai H, Uemura N. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice. Life Sciences 2019;228:251-7. [DOI: 10.1016/j.lfs.2019.05.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
219 Povsic M, Wong OY, Perry R, Bottomley J. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). Adv Ther 2019;36:1574-94. [PMID: 31065991 DOI: 10.1007/s12325-019-00960-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
220 Weinstein G, Davis-Plourde K, Himali JJ, Zelber-Sagi S, Beiser AS, Seshadri S. Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study. Liver Int 2019;39:1713-21. [PMID: 31155826 DOI: 10.1111/liv.14161] [Cited by in Crossref: 15] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
221 Ostovaneh MR, Ambale-Venkatesh B, Fuji T, Bakhshi H, Shah R, Murthy VL, Tracy RP, Guallar E, Wu CO, Bluemke DA, Lima JAC. Association of Liver Fibrosis With Cardiovascular Diseases in the General Population: The Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging 2018;11:e007241. [PMID: 29523555 DOI: 10.1161/CIRCIMAGING.117.007241] [Cited by in Crossref: 28] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
222 Culafic M, Vezmar Kovacevic S, Dopsaj V, Stulic M, Vlaisavljevic Z, Miljkovic B, Culafic D. A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests. Medicina (Kaunas). 2019;55. [PMID: 31163711 DOI: 10.3390/medicina55060243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
223 Brandman D. Who Should Treat Fatty Liver Disease: Primary Care or Hepatology? Clin Liver Dis (Hoboken) 2019;13:158-61. [PMID: 31316762 DOI: 10.1002/cld.766] [Reference Citation Analysis]
224 Koo BK, Allison MA, Criqui MH, Denenberg JO, Wright CM. The association between liver fat and systemic calcified atherosclerosis. J Vasc Surg 2020;71:204-211.e4. [PMID: 31153702 DOI: 10.1016/j.jvs.2019.03.044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
225 El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;20:E2215. [PMID: 31064058 DOI: 10.3390/ijms20092215] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
226 Mumtaz S, Schomaker N, Von Roenn N. Pro: Noninvasive Imaging Has Replaced Biopsy as the Gold Standard in the Evaluation of Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2019;13:111-3. [PMID: 31061704 DOI: 10.1002/cld.750] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
227 Baik M, Kim SU, Nam HS, Heo JH, Kim YD. The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke. Front Neurol 2019;10:375. [PMID: 31031700 DOI: 10.3389/fneur.2019.00375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
228 Zsóri G, Illés D, Ivány E, Kosár K, Holzinger G, Tajti M, Pálinkás E, Szabovik G, Nagy A, Palkó A, Czakó L. In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. Metab Syndr Relat Disord 2019;17:289-95. [PMID: 31013454 DOI: 10.1089/met.2018.0086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
229 Kamarajah SK, Khoo S, Chan WK, Sthaneshwar P, Nik Mustapha NR, Mahadeva S. Limited applicability of cathepsin D for the diagnosis and monitoring of non-alcoholic steatohepatitis. JGH Open 2019;3:417-24. [PMID: 31633048 DOI: 10.1002/jgh3.12178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
230 Green CJ, Marjot T, Tomlinson JW, Hodson L. Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis? Diabetes Obes Metab 2019;21:749-60. [DOI: 10.1111/dom.13592] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
231 Lai M, Afdhal NH. Liver Fibrosis Determination. Gastroenterol Clin North Am. 2019;48:281-289. [PMID: 31046975 DOI: 10.1016/j.gtc.2019.02.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
232 Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85. [PMID: 28670712 DOI: 10.1111/jgh.13857] [Cited by in Crossref: 165] [Cited by in F6Publishing: 202] [Article Influence: 55.0] [Reference Citation Analysis]
233 Okamura K, Okuda T, Takamiya Y, Shirai K, Urata H. High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. Heart Vessels 2019;34:1559-69. [PMID: 30919112 DOI: 10.1007/s00380-019-01391-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
234 van den Berg EH, Flores-Guerrero JL, Gruppen EG, de Borst MH, Wolak-Dinsmore J, Connelly MA, Bakker SJL, Dullaart RPF. Non-Alcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: Role of Circulating Branched-Chain Amino Acids. Nutrients 2019;11:E705. [PMID: 30917546 DOI: 10.3390/nu11030705] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 8.7] [Reference Citation Analysis]
235 Önnerhag K, Hartman H, Nilsson PM, Lindgren S. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scandinavian Journal of Gastroenterology 2019;54:328-34. [DOI: 10.1080/00365521.2019.1583366] [Cited by in Crossref: 20] [Cited by in F6Publishing: 32] [Article Influence: 6.7] [Reference Citation Analysis]
236 Szanto KB, Li J, Cordero P, Oben JA. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019;12:357-367. [PMID: 30936733 DOI: 10.2147/dmso.s182331] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
237 Chen PC, Kao WY, Cheng YL, Wang YJ, Hou MC, Wu JC, Su CW. The correlation between fatty liver disease and chronic kidney disease. J Formos Med Assoc. 2020;119:42-50. [PMID: 30876789 DOI: 10.1016/j.jfma.2019.02.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
238 Zhao Y, Zhang L, Ouyang X, Jiang Z, Xie Z, Fan L, Zhu D, Li L. Advanced oxidation protein products play critical roles in liver diseases. Eur J Clin Invest 2019;:e13098. [PMID: 30838641 DOI: 10.1111/eci.13098] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
239 Kim MC, Park JG, Jang BI, Lee HJ, Lee WK. Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease. Medicine (Baltimore) 2019;98:e14139. [PMID: 30732129 DOI: 10.1097/MD.0000000000014139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
240 Farzin L, Asghari S, Rafraf M, Asghari-Jafarabadi M, Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res 2020;90:279-89. [PMID: 30789808 DOI: 10.1024/0300-9831/a000528] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
241 Minocha S, Villeneuve D, Praz V, Moret C, Lopes M, Pinatel D, Rib L, Guex N, Herr W. Rapid Recapitulation of Nonalcoholic Steatohepatitis upon Loss of Host Cell Factor 1 Function in Mouse Hepatocytes. Mol Cell Biol 2019;39:e00405-18. [PMID: 30559308 DOI: 10.1128/MCB.00405-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
242 Shah RA, Kowdley KV. Serum ferritin as a biomarker for NAFLD: ready for prime time? Hepatol Int 2019;13:110-2. [PMID: 30739262 DOI: 10.1007/s12072-019-09934-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
243 Fitzpatrick E. Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum. Proc Nutr Soc 2019;78:362-71. [DOI: 10.1017/s0029665118002914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
244 Miyauchi S, Miyake T, Miyazaki M, Eguchi T, Niiya T, Yamamoto S, Senba H, Furukawa S, Matsuura B, Hiasa Y. Insulin-like growth factor-1 is inversely associated with liver fibrotic markers in patients with type 2 diabetes mellitus. J Diabetes Investig 2019;10:1083-91. [PMID: 30592792 DOI: 10.1111/jdi.13000] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
245 Yu C, Wang L, Xue H, Lin H, Li Y, Chan S. Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes. Clinics and Research in Hepatology and Gastroenterology 2019;43:58-66. [DOI: 10.1016/j.clinre.2018.08.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
246 Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis 2019;282:110-20. [PMID: 30731283 DOI: 10.1016/j.atherosclerosis.2019.01.029] [Cited by in Crossref: 36] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
247 Buznytska OV; Kharkіv Medical Academy of Postgraduate Education,V. N. Karazin Kharkіv National University, Ukraine. Diagnostic significance of biochemical indicators of liver fibrogenesis in adolescents with obesity. Ukr Biochem J 2019;91:74-9. [DOI: 10.15407/ubj91.01.074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
248 Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. Dig Dis Sci 2020;65:623-31. [PMID: 30684076 DOI: 10.1007/s10620-019-5477-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 21.7] [Reference Citation Analysis]
249 Chang Y, Cho YK, Cho J, Jung H, Yun KE, Ahn J, Sohn CI, Shin H, Ryu S. Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study. Am J Gastroenterol 2019;114:620-9. [DOI: 10.14309/ajg.0000000000000074] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
250 Reisberg S, Galwey N, Avillach P, Sahlqvist AS, Kolberg L, Mägi R, Esko T, Vilo J, James G. Comparison of variation in frequency for SNPs associated with asthma or liver disease between Estonia, HapMap populations and the 1000 genome project populations. Int J Immunogenet 2019;46:49-58. [PMID: 30659741 DOI: 10.1111/iji.12413] [Reference Citation Analysis]
251 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1264-1281.e4. [PMID: 30660725 DOI: 10.1053/j.gastro.2018.12.036] [Cited by in Crossref: 310] [Cited by in F6Publishing: 462] [Article Influence: 103.3] [Reference Citation Analysis]
252 Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019;38:485-521. [PMID: 30712783 DOI: 10.1016/j.clnu.2018.12.022] [Cited by in F6Publishing: 181] [Reference Citation Analysis]
253 Yeo SC, Ong WM, Cheng KSA, Tan CH. Weight Loss After Bariatric Surgery Predicts an Improvement in the Non-alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score. OBES SURG 2019;29:1295-300. [DOI: 10.1007/s11695-018-03676-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
254 Fernando JN, Alba RL, Alba W. Factors associated with the Severity of Findings on Hepatic Transient Elastography among Persons with Type 2 Diabetes and Fatty Liver. J ASEAN Fed Endocr Soc 2019;34:134-43. [PMID: 33442148 DOI: 10.15605/jafes.034.02.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
255 Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, Yun KE, Shin H, Ryu S. Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology 2019;69:64-75. [PMID: 30019340 DOI: 10.1002/hep.30170] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 21.7] [Reference Citation Analysis]
256 Konerman MA, Walden P, Joseph M, Jackson EA, Lok AS, Rubenfire M. Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019;49:296-307. [PMID: 30561027 DOI: 10.1111/apt.15063] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
257 Ghaeni Pasavei A, Mohebbati R, Jalili-Nik M, Mollazadeh H, Ghorbani A, Nosrati Tirkani A, Taraz Jamshidi S, Hashemy SI, Heidarian Miri H, Soukhtanloo M. Effects of Rhus coriaria L. hydroalcoholic extract on the lipid and antioxidant profile in high fat diet-induced hepatic steatosis in rats. Drug Chem Toxicol 2021;44:75-83. [PMID: 33319629 DOI: 10.1080/01480545.2018.1533024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
258 Hui ST, Kurt Z, Tuominen I, Norheim F, C Davis R, Pan C, Dirks DL, Magyar CE, French SW, Chella Krishnan K, Sabir S, Campos-Pérez F, Méndez-Sánchez N, Macías-Kauffer L, León-Mimila P, Canizales-Quinteros S, Yang X, Beaven SW, Huertas-Vazquez A, Lusis AJ. The Genetic Architecture of Diet-Induced Hepatic Fibrosis in Mice. Hepatology 2018;68:2182-96. [PMID: 29907965 DOI: 10.1002/hep.30113] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
259 De Martin S, Gabbia D, Carrara M, Ferri N. The Brown Algae Fucus vesiculosus and Ascophyllum nodosum Reduce Metabolic Syndrome Risk Factors: A Clinical Study. Natural Product Communications 2018;13:1934578X1801301. [DOI: 10.1177/1934578x1801301228] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
260 Jensen T, Wieland A, Cree-Green M, Nadeau K, Sullivan S. Clinical workup of fatty liver for the primary care provider. Postgrad Med 2019;131:19-30. [PMID: 30496690 DOI: 10.1080/00325481.2019.1546532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
261 Oikonomou D, Georgiopoulos G, Katsi V, Kourek C, Tsioufis C, Alexopoulou A, Koutli E, Tousoulis D. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? Eur J Gastroenterol Hepatol. 2018;30:979-985. [PMID: 30048367 DOI: 10.1097/meg.0000000000001191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 8.3] [Reference Citation Analysis]
262 De Lucia Rolfe E, Brage S, Sleigh A, Finucane F, Griffin SJ, Wareham NJ, Ong KK, Forouhi NG. Validity of ultrasonography to assess hepatic steatosis compared to magnetic resonance spectroscopy as a criterion method in older adults. PLoS One 2018;13:e0207923. [PMID: 30475885 DOI: 10.1371/journal.pone.0207923] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
263 Belemets N, Kobyliak N, Falalyeyeva T, Kuryk O, Sulaieva O, Vovk T, Beregova T, Ostapchenko L. Polyphenol Compounds Melanin Prevented Hepatic Inflammation in Rats with Experimental Obesity. Natural Product Communications 2018;13:1934578X1801301. [DOI: 10.1177/1934578x1801301118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
264 Mazhar K. The Future of Nonalcoholic Fatty Liver Disease Treatment. Med Clin North Am 2019;103:57-69. [PMID: 30466676 DOI: 10.1016/j.mcna.2018.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
265 Sharma V, Juglan K. Automated Classification of Fatty and Normal Liver Ultrasound Images Based on Mutual Information Feature Selection. IRBM 2018;39:313-23. [DOI: 10.1016/j.irbm.2018.09.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
266 Kobyliak N, Abenavoli L, Falalyeyeva T, Beregova T. Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease. Ann Hepatol. 2018;17:153-161. [PMID: 29311399 DOI: 10.5604/01.3001.0010.7547] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
267 Zubair R, Mirza M, Iftikhar J, Saeed N. Frequency of incidental fatty liver on ultrasound and its association with diabetes mellitus and hypertension. Pak J Med Sci 2018;34:1137-41. [PMID: 30344564 DOI: 10.12669/pjms.345.15102] [Reference Citation Analysis]
268 Anderson EJ, Vistoli G, Katunga LA, Funai K, Regazzoni L, Monroe TB, Gilardoni E, Cannizzaro L, Colzani M, De Maddis D, Rossoni G, Canevotti R, Gagliardi S, Carini M, Aldini G. A carnosine analog mitigates metabolic disorders of obesity by reducing carbonyl stress. J Clin Invest 2018;128:5280-93. [PMID: 30226473 DOI: 10.1172/JCI94307] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 11.5] [Reference Citation Analysis]
269 Jirapinyo P, Thompson CC. Treatment of NASH with Gastric Bypass. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0653-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
270 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
271 Ooi GJ, Burton PR, Bayliss J, Raajendiran A, Earnest A, Laurie C, Kemp WW, Mclean CA, Roberts SK, Watt MJ, Brown WA. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study. OBES SURG 2019;29:99-108. [DOI: 10.1007/s11695-018-3479-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
272 Tomasiewicz K, Flisiak R, Halota W, Jaroszewicz J, Lebensztejn D, Lisik W, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tronina O; Recommendations of the Polish Group of Experts for Non-Alcoholic Fatty Liver Disease (PGE-NAFLD). Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clin Exp Hepatol 2018;4:153-7. [PMID: 30324139 DOI: 10.5114/ceh.2018.78118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
273 Yoshida Y, Furukawa J, Naito S, Higashino K, Numata Y, Shinohara Y. Identification of unique glycoisoforms of vitamin D-binding protein and haptoglobin as biomarker candidates in hepatocarcinogenesis of STAM mice. Glycoconj J 2018;35:467-76. [DOI: 10.1007/s10719-018-9838-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
274 Albhaisi S, Issa D, Alkhouri N. Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden. Hepatobiliary Surg Nutr 2018;7:389-91. [PMID: 30498715 DOI: 10.21037/hbsn.2018.07.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
275 Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, Hatcho K, Lawitz E, Lopez R, Feldstein AE. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. PLoS One 2018;13:e0202226. [PMID: 30161179 DOI: 10.1371/journal.pone.0202226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
276 Guo WW, Wang X, Chen XQ, Ba YY, Zhang N, Xu RR, Zhao WW, Wu X. Flavonones from Penthorum chinense Ameliorate Hepatic Steatosis by Activating the SIRT1/AMPK Pathway in HepG2 Cells. Int J Mol Sci 2018;19:E2555. [PMID: 30154382 DOI: 10.3390/ijms19092555] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
277 Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol 2018; 10(8): 530-542 [PMID: 30190781 DOI: 10.4254/wjh.v10.i8.530] [Cited by in Crossref: 115] [Cited by in F6Publishing: 101] [Article Influence: 28.8] [Reference Citation Analysis]
278 Jensen T, Niwa K, Hisatome I, Kanbay M, Andres-Hernando A, Roncal-Jimenez CA, Sato Y, Garcia G, Ohno M, Lanaspa MA, Johnson RJ, Kuwabara M. Increased Serum Uric Acid over five years is a Risk Factor for Developing Fatty Liver. Sci Rep. 2018;8:11735. [PMID: 30082907 DOI: 10.1038/s41598-018-30267-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
279 Yu AH, Duan-Mu YY, Zhang Y, Wang L, Guo Z, Yu YQ, Wang YS, Cheng XG. Correlation between Non-Alcoholic Fatty Liver Disease and Visceral Adipose Tissue in Non-Obese Chinese Adults: A CT Evaluation. Korean J Radiol. 2018;19:923-929. [PMID: 30174482 DOI: 10.3348/kjr.2018.19.5.923] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
280 Fujiwara Y, Kuroda H, Abe T, Ishida K, Oguri T, Noguchi S, Sugai T, Kamiyama N, Takikawa Y. The B-Mode Image-Guided Ultrasound Attenuation Parameter Accurately Detects Hepatic Steatosis in Chronic Liver Disease. Ultrasound Med Biol. 2018;44:2223-2232. [PMID: 30077415 DOI: 10.1016/j.ultrasmedbio.2018.06.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 54] [Article Influence: 8.5] [Reference Citation Analysis]
281 Wang G, Corwin MT, Olson KA, Badawi RD, Sarkar S. Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol. 2018;63:155004. [PMID: 29847315 DOI: 10.1088/1361-6560/aac8cb] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
282 Tsai E, Lee TP. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2018;22:73-92. [PMID: 29128062 DOI: 10.1016/j.cld.2017.08.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 8.5] [Reference Citation Analysis]
283 Gunn NT, Shiffman ML. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom. Clin Liver Dis 2018;22:109-19. [PMID: 29128050 DOI: 10.1016/j.cld.2017.08.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
284 Martins E, Oliveira A. NAFLD and cardiovascular disease. Porto Biomed J 2018;3:e2. [PMID: 31595238 DOI: 10.1016/j.pbj.0000000000000002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
285 Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, Hwang JP, Barranco-Fragoso B, Cordova-Gallardo J. New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis. Int J Mol Sci. 2018;19. [PMID: 30011790 DOI: 10.3390/ijms19072034] [Cited by in Crossref: 61] [Cited by in F6Publishing: 70] [Article Influence: 15.3] [Reference Citation Analysis]
286 Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896-904. [PMID: 29886156 DOI: 10.1016/j.jhep.2018.05.036] [Cited by in Crossref: 381] [Cited by in F6Publishing: 547] [Article Influence: 95.3] [Reference Citation Analysis]
287 Kartoun U. Toward an accelerated adoption of data-driven findings in medicine: Research, skepticism, and the need to speed up public visibility of data-driven findings. Med Health Care and Philos 2019;22:153-7. [DOI: 10.1007/s11019-018-9845-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
288 Franch-Nadal J, Caballeria L, Mata-Cases M, Mauricio D, Giraldez-García C, Mancera J, Goday A, Mundet-Tudurí X, Regidor E; PREDAPS Study Group. Fatty liver index is a predictor of incident diabetes in patients with prediabetes: The PREDAPS study. PLoS One 2018;13:e0198327. [PMID: 29856820 DOI: 10.1371/journal.pone.0198327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
289 George ES, Roberts SK, Nicoll AJ, Reddy A, Paris T, Itsiopoulos C, Tierney AC. Non-alcoholic fatty liver disease patients attending two metropolitan hospitals in Melbourne, Australia: high risk status and low prevalence. Intern Med J 2018;48:1369-76. [PMID: 29845719 DOI: 10.1111/imj.13973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
290 Bajantri B, Lvovsky D. A Case of Concomitant Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis Treated With CPAP Therapy. Gastroenterology Res. 2018;11:252-259. [PMID: 29915639 DOI: 10.14740/gr1033w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
291 Simon TG, Corey KE, Cannon CP, Blazing M, Park JG, O'Donoghue ML, Chung RT, Giugliano RP. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol 2018;270:245-52. [PMID: 29903515 DOI: 10.1016/j.ijcard.2018.05.087] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
292 Silva AKS, Peixoto CA. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cell Mol Life Sci. 2018;75:2951-2961. [PMID: 29789866 DOI: 10.1007/s00018-018-2838-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
293 Wang C, Liu S, Lu L, Liao S, Yue H, Dong Q, Xin Y, Xuan S. Association Between Four ABCA1 gene Polymorphisms and Risk of Non-Alcoholic Fatty Liver Disease in a Chinese Han Population. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.66149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
294 Barzin M, Kalantar Motamedi MA, Khalaj A, Serahati S, Khalili D, Morakabati A, Valizadeh M, Azizi F, Hosseinpanah F, Rakhshani N. Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Bariatric Patients: Tehran Obesity Treatment Study (TOTS). Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.64380] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
295 Jung TW, Park HS, Choi GH, Kim D, Jeong JH, Lee T. Chitinase‐3‐like protein 1 ameliorates atherosclerotic responses via PPARδ‐mediated suppression of inflammation and ER stress. J Cell Biochem 2018;119:6795-805. [DOI: 10.1002/jcb.26873] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
296 Lee CH, Choi SH, Chung GE, Park B, Kwak MS. Nonalcoholic fatty liver disease is associated with decreased lung function. Liver Int 2018;38:2091-100. [PMID: 29660233 DOI: 10.1111/liv.13860] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
297 Aller R, Fernández-rodríguez C, lo Iacono O, Bañares R, Abad J, Carrión JA, García-monzón C, Caballería J, Berenguer M, Rodríguez-perálvarez M, Miranda JL, Vilar-gómez E, Crespo J, García-cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterología y Hepatología (English Edition) 2018;41:328-49. [DOI: 10.1016/j.gastre.2018.05.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
298 Singh A, Kumar MS, Jaryal AK, Ranjan P, Deepak KK, Sharma S, Lakshmy R, Pandey RM, Vikram NK. Diabetic status and grade of nonalcoholic fatty liver disease are associated with lower baroreceptor sensitivity in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2017;29:956-61. [PMID: 28471821 DOI: 10.1097/MEG.0000000000000898] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
299 VanWagner LB, Ning H, Allen NB, Siddique J, Carson AP, Bancks MP, Lewis CE, Carr JJ, Speliotes E, Terrault NA, Rinella ME, Vos MB, Lloyd-Jones DM. Twenty-five-year trajectories of insulin resistance and pancreatic β-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int 2018;38:2069-81. [PMID: 29608255 DOI: 10.1111/liv.13747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
300 Yu Q, Jiang Z, Zhang L. Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease. Pharmacol Ther 2018;190:81-90. [PMID: 29684468 DOI: 10.1016/j.pharmthera.2018.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
301 Harlow KE, Africa JA, Wells A, Belt PH, Behling CA, Jain AK, Molleston JP, Newton KP, Rosenthal P, Vos MB, Xanthakos SA, Lavine JE, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. J Pediatr 2018;198:76-83.e2. [PMID: 29661561 DOI: 10.1016/j.jpeds.2018.02.038] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
302 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
303 Bonafini S, Tagetti A, Gaudino R, Cavarzere P, Montagnana M, Danese E, Benati M, Ramaroli DA, Raimondi S, Giontella A, Mantovani A, Donato A, Dalbeni A, Minuz P, Antoniazzi F, Maffeis C, Fava C. Individual fatty acids in erythrocyte membranes are associated with several features of the metabolic syndrome in obese children. Eur J Nutr 2019;58:731-42. [PMID: 29594475 DOI: 10.1007/s00394-018-1677-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
304 Verdelho Machado M, Diehl AM. The hedgehog pathway in nonalcoholic fatty liver disease. Crit Rev Biochem Mol Biol 2018;53:264-78. [PMID: 29557675 DOI: 10.1080/10409238.2018.1448752] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
305 Del Campo JA, Gallego-Durán R, Gallego P, Grande L. Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). Int J Mol Sci 2018;19:E911. [PMID: 29562725 DOI: 10.3390/ijms19030911] [Cited by in Crossref: 50] [Cited by in F6Publishing: 59] [Article Influence: 12.5] [Reference Citation Analysis]
306 Kobyliak N, Falalyeyeva T, Bodnar P, Beregova T. Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity. Probiotics Antimicrob Proteins. 2017;9:123-130. [PMID: 27660157 DOI: 10.1007/s12602-016-9230-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
307 Mandelia C, Kabbany MN, Conjeevaram Selvakumar PK, Alkhouri N. The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease. Biomark Med 2018;12:265-73. [PMID: 29517271 DOI: 10.2217/bmm-2017-0038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
308 Singh A, Le P, Peerzada MM, Lopez R, Alkhouri N. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients. Journal of Clinical Gastroenterology 2018;52:268-72. [DOI: 10.1097/mcg.0000000000000905] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
309 Ofosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol. 2018;31:288-295. [PMID: 29720854 DOI: 10.20524/aog.2018.0240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
310 Gerage AM, Ritti-dias RM, Balagopal PB, Conceição RDDO, Umpierre D, Santos RD, Cucato GG, Bittencourt MS. Physical activity levels and hepatic steatosis: A longitudinal follow-up study in adults: Physical activity and hepatic steatosis. Journal of Gastroenterology and Hepatology 2018;33:741-6. [DOI: 10.1111/jgh.13965] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
311 Spanos C, Maldonado EM, Fisher CP, Leenutaphong P, Oviedo-Orta E, Windridge D, Salguero FJ, Bermúdez-Fajardo A, Weeks ME, Evans C, Corfe BM, Rabbani N, Thornalley PJ, Miller MH, Wang H, Dillon JF, Quaglia A, Dhawan A, Fitzpatrick E, Moore JB. Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease. Proteome Sci 2018;16:4. [PMID: 29456458 DOI: 10.1186/s12953-018-0131-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
312 Williams KH, Burns K, Twigg SM. Differing clinical phenotype for higher alanine-aminotransferase (ALT) compared with high-risk NAFLD fibrosis score in type 2 diabetes mellitus. J Diabetes Complications 2018;32:321-4. [PMID: 29398327 DOI: 10.1016/j.jdiacomp.2017.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
313 Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, Papatheodoridis G, Combet E. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Metabolism. 2018;83:120-127. [PMID: 29409822 DOI: 10.1016/j.metabol.2018.01.023] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
314 Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrology Dialysis Transplantation 2019;34:449-57. [DOI: 10.1093/ndt/gfx381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
315 Kamarajah SK, Chan WK, Nik Mustapha NR, Mahadeva S. Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease. Hepatol Int 2018;12:44-55. [PMID: 29372507 DOI: 10.1007/s12072-018-9843-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
316 Yamada K, Mizukoshi E, Seike T, Horii R, Kitahara M, Sunagozaka H, Arai K, Yamashita T, Honda M, Kaneko S. Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease. PLoS One 2018;13:e0191026. [PMID: 29342182 DOI: 10.1371/journal.pone.0191026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
317 Mazzolini G, Atorrasagasti C, Onorato A, Peixoto E, Schlattjan M, Sowa JP, Sydor S, Gerken G, Canbay A. SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease. Sci Rep 2018;8:725. [PMID: 29335425 DOI: 10.1038/s41598-017-18981-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
318 Chan WK, Treeprasertsuk S, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Fan JG, Song MJ, Yoon SK, Dan YY, Lesmana L, Ho KY, Goh KL, Wong VW. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. Aliment Pharmacol Ther. 2018;47:816-825. [PMID: 29333610 DOI: 10.1111/apt.14506] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
319 Singh A, Le P, Lopez R, Alkhouri N. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients. Hepatol Int 2018;12:37-43. [PMID: 29318450 DOI: 10.1007/s12072-017-9840-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
320 Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, Gedulin B, van Vliet AA, Dorenbaum A, Palmer M. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC Gastroenterol 2018;18:3. [PMID: 29304731 DOI: 10.1186/s12876-017-0736-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
321 Winn NC, Liu Y, Rector RS, Parks EJ, Ibdah JA, Kanaley JA. Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity — A randomized trial. Metabolism 2018;78:128-40. [DOI: 10.1016/j.metabol.2017.08.012] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 15.0] [Reference Citation Analysis]
322 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 2734] [Cited by in F6Publishing: 2586] [Article Influence: 683.5] [Reference Citation Analysis]
323 Nampoothiri RV, Duseja A, Rathi M, Agrawal S, Sachdeva N, Mehta M, Dhaliwal HS, Dhiman RK, Chawla Y. Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease. J Clin Exp Hepatol. 2019;9:22-28. [PMID: 30765935 DOI: 10.1016/j.jceh.2017.12.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
324 Kim SS, Cho HJ, Kim HJ, Kang DR, Berry JR, Kim JH, Yang MJ, Lim SG, Kim S, Cheong JY, Cho SW. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Dig Liver Dis. 2018;50:370-377. [PMID: 29398414 DOI: 10.1016/j.dld.2017.12.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
325 Mandelia C, Collyer E, Mansoor S, Lopez R, Lappe S, Nobili V, Alkhouri N. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2016;63:181-187. [PMID: 26835904 DOI: 10.1097/mpg.0000000000001136] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
326 Watanabe K, Ohta M, Takayama H, Tada K, Shitomi Y, Kawasaki T, Kawano Y, Endo Y, Iwashita Y, Inomata M. Effects of Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease in an Obese Rat Model. OBES SURG 2018;28:1532-9. [DOI: 10.1007/s11695-017-3052-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
327 Davies JMS, Cillard J, Friguet B, Cadenas E, Cadet J, Cayce R, Fishmann A, Liao D, Bulteau AL, Derbré F, Rébillard A, Burstein S, Hirsch E, Kloner RA, Jakowec M, Petzinger G, Sauce D, Sennlaub F, Limon I, Ursini F, Maiorino M, Economides C, Pike CJ, Cohen P, Salvayre AN, Halliday MR, Lundquist AJ, Jakowec NA, Mechta-Grigoriou F, Mericskay M, Mariani J, Li Z, Huang D, Grant E, Forman HJ, Finch CE, Sun PY, Pomatto LCD, Agbulut O, Warburton D, Neri C, Rouis M, Cillard P, Capeau J, Rosenbaum J, Davies KJA. The Oxygen Paradox, the French Paradox, and age-related diseases. Geroscience 2017;39:499-550. [PMID: 29270905 DOI: 10.1007/s11357-017-0002-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
328 Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Nordstrom BL. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 2017;9:679-88. [PMID: 29276410 DOI: 10.2147/CLEP.S144368] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
329 Czul F, Bhamidimarri KR. Noninvasive Markers to Assess Liver Fibrosis. J Clin Gastroenterol 2016;50:445-57. [PMID: 27105176 DOI: 10.1097/MCG.0000000000000534] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
330 Kwak MS, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J Intern Med 2018;33:64-74. [PMID: 29202557 DOI: 10.3904/kjim.2017.343] [Cited by in Crossref: 32] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
331 Wang N, Kong R, Luo H, Xu X, Lu J. Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease. PPAR Res 2017;2017:6561701. [PMID: 29358945 DOI: 10.1155/2017/6561701] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
332 Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305-315. [PMID: 29154965 DOI: 10.1016/j.jhep.2017.11.013] [Cited by in Crossref: 190] [Cited by in F6Publishing: 253] [Article Influence: 38.0] [Reference Citation Analysis]
333 Jaruvongvanich V, Wijarnpreecha K, Ungprasert P. The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of cohort study. Clinics and Research in Hepatology and Gastroenterology 2017;41:629-34. [DOI: 10.1016/j.clinre.2017.03.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
334 Hu M, Phan F, Bourron O, Ferré P, Foufelle F. Steatosis and NASH in type 2 diabetes. Biochimie 2017;143:37-41. [DOI: 10.1016/j.biochi.2017.10.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
335 Wah Kheong C, Nik Mustapha NR, Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2017;15:1940-1949.e8. [DOI: 10.1016/j.cgh.2017.04.016] [Cited by in Crossref: 89] [Cited by in F6Publishing: 80] [Article Influence: 17.8] [Reference Citation Analysis]
336 Sanyal A, Cusi K, Hartman ML, Zhang S, Bastyr EJ 3rd, Bue-Valleskey JM, Chang AM, Haupt A, Jacober SJ, Konrad RJ, Zhang Q, Hoogwerf BJ. Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins. J Investig Med 2018;66:661-8. [PMID: 29167192 DOI: 10.1136/jim-2017-000609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
337 Yoneda M, Imajo K, Takahashi H, Ogawa Y, Eguchi Y, Sumida Y, Yoneda M, Kawanaka M, Saito S, Tokushige K, Nakajima A. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol 2018;53:181-96. [PMID: 29177681 DOI: 10.1007/s00535-017-1414-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 9.2] [Reference Citation Analysis]
338 Chang HT, Pan HJ, Lee CH. Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients. Clin Breast Cancer 2018;18:e677-85. [PMID: 29287963 DOI: 10.1016/j.clbc.2017.11.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
339 Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391-397. [PMID: 29984130 DOI: 10.1007/s11901-017-0378-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 64] [Article Influence: 10.2] [Reference Citation Analysis]
340 Friedrich-Rust M, Schoelzel F, Maier S, Seeger F, Rey J, Fichtlscherer S, Herrmann E, Zeuzem S, Bojunga J. Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study. PLoS One 2017;12:e0186720. [PMID: 29073252 DOI: 10.1371/journal.pone.0186720] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
341 Ahmed MH, Noor SK, Bushara SO, Husain NE, Elmadhoun WM, Ginawi IA, Osman MM, Mahmoud AO, Almobarak AO. Non-Alcoholic Fatty Liver Disease in Africa and Middle East: An Attempt to Predict the Present and Future Implications on the Healthcare System. Gastroenterology Res 2017;10:271-9. [PMID: 29118867 DOI: 10.14740/gr913w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
342 Jiang Y, Han T, Zhang ZG, Li M, Qi FX, Zhang Y, Ji YL. Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease. Chronic Dis Transl Med 2017;3:165-8. [PMID: 29063072 DOI: 10.1016/j.cdtm.2017.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
343 Yang H, Chang Y, Park S, Jung YS, Park JH, Park DI, Cho YK, Ryu S, Sohn CI. Nonalcoholic Fatty Liver Disease Is Associated with Increased Risk of Reflux Esophagitis. Dig Dis Sci 2017;62:3605-13. [DOI: 10.1007/s10620-017-4805-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
344 Khan RS, Newsome PN. Editorial: optimising non-invasive screening for advanced liver fibrosis in NAFLD. Aliment Pharmacol Ther 2017;46:899-900. [PMID: 29023886 DOI: 10.1111/apt.14267] [Reference Citation Analysis]
345 VanWagner LB, Khan SS, Ning H, Siddique J, Lewis CE, Carr JJ, Vos MB, Speliotes E, Terrault NA, Rinella ME, Lloyd-Jones DM, Allen NB. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int 2018;38:706-14. [PMID: 28963767 DOI: 10.1111/liv.13603] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
346 Sakpal M, Satsangi S, Mehta M, Duseja A, Bhadada S, Das A, Dhiman RK, Chawla YK. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial. JGH Open. 2017;1:62-67. [PMID: 30483536 DOI: 10.1002/jgh3.12010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
347 Esterson YB, Grimaldi GM. Radiologic Imaging in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis. 2018;22:93-108. [PMID: 29128063 DOI: 10.1016/j.cld.2017.08.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
348 Jun DW, Kim SG, Park SH, Jin SY, Lee JS, Lee JW, Kim MY, Choi DH, Cho YK, Yeon JE, Sohn JH; Korean NAFLD study group (KNSG). External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients. J Gastroenterol Hepatol. 2017;32:1094-1099. [PMID: 27859583 DOI: 10.1111/jgh.13648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
349 Yoshihisa A, Sato Y, Yokokawa T, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Saitoh SI, Takeishi Y. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail 2018;5:262-70. [PMID: 28967709 DOI: 10.1002/ehf2.12222] [Cited by in Crossref: 41] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
350 Ochoa C. E, Calambás F. Hígado graso no alcohólico en consulta de gastroenterología. Repertorio de Medicina y Cirugía 2017;26:225-30. [DOI: 10.1016/j.reper.2017.10.005] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
351 Parry SA, Hodson L. Influence of dietary macronutrients on liver fat accumulation and metabolism. J Investig Med 2017;65:1102-15. [PMID: 28947639 DOI: 10.1136/jim-2017-000524] [Cited by in Crossref: 55] [Cited by in F6Publishing: 64] [Article Influence: 11.0] [Reference Citation Analysis]
352 Akinkugbe AA, Slade GD, Barritt AS, Cole SR, Offenbacher S, Petersmann A, Kocher T, Lerch MM, Mayerle J, Völzke H, Heiss G, Holtfreter B. Periodontitis and Non-alcoholic Fatty Liver Disease, a population-based cohort investigation in the Study of Health in Pomerania. J Clin Periodontol 2017;44:1077-87. [PMID: 28804947 DOI: 10.1111/jcpe.12800] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
353 Sinn DH, Kang D, Jang HR, Gu S, Cho SJ, Paik SW, Ryu S, Chang Y, Lazo M, Guallar E, Cho J, Gwak GY. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. J Hepatol. 2017;67:1274-1280. [PMID: 28870674 DOI: 10.1016/j.jhep.2017.08.024] [Cited by in Crossref: 66] [Cited by in F6Publishing: 74] [Article Influence: 13.2] [Reference Citation Analysis]
354 Takyar V, Nath A, Beri A, Gharib AM, Rotman Y. How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool. Hepatology 2017;66:825-33. [PMID: 28470683 DOI: 10.1002/hep.29247] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
355 Liyanagedera S, Williams RP, Veraldi S, Nobili V, Mann JP. The pharmacological management of NAFLD in children and adolescents. Expert Rev Clin Pharmacol 2017;10:1225-37. [PMID: 28803504 DOI: 10.1080/17512433.2017.1365599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
356 VanWagner LB, Ning H, Allen NB, Ajmera V, Lewis CE, Carr JJ, Lloyd-Jones DM, Terrault NA, Siddique J. Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2017;153:1260-1272.e3. [PMID: 28802566 DOI: 10.1053/j.gastro.2017.08.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
357 Cui C, Deng J, Yan L, Liu Y, Fan J, Mu H, Sun H, Wang Y, Han J. Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation. Journal of Ethnopharmacology 2017;208:24-35. [DOI: 10.1016/j.jep.2017.06.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
358 Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017;177:633-640. [PMID: 28241279 DOI: 10.1001/jamainternmed.2016.9607] [Cited by in Crossref: 151] [Cited by in F6Publishing: 186] [Article Influence: 30.2] [Reference Citation Analysis]
359 Shouhed D, Steggerda J, Burch M, Noureddin M. The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2017;11:797-811. [PMID: 28712339 DOI: 10.1080/17474124.2017.1355731] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
360 Aoyama T, Takada H, Uchiyama A, Kon K, Yamashina S, Ikejima K, Ban H, Watanabe S. A Customized Online Nutrition Guidance System Is Effective for Treating Patients with Nonalcoholic Fatty Liver Disease by Supporting Continuity of Diet Therapy at Home: A Pilot Study. Intern Med 2017;56:1651-6. [PMID: 28674352 DOI: 10.2169/internalmedicine.56.8187] [Reference Citation Analysis]
361 Cheah MC, McCullough AJ, Goh GB. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5:261-271. [PMID: 28936407 DOI: 10.14218/jcth.2017.00009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
362 Bush H, Golabi P, Younossi ZM. Pediatric Non-Alcoholic Fatty Liver Disease. Children (Basel) 2017;4:E48. [PMID: 28598410 DOI: 10.3390/children4060048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
363 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol 2017; 9(16): 715-732 [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 378] [Cited by in F6Publishing: 338] [Article Influence: 75.6] [Reference Citation Analysis]
364 Bakulin IG, Sandler YG, Vinnitskaya EV, Keiyan VA, Rodionova SV, Rotin DL. [Diabetes mellitus and nonalcoholic fatty liver disease: The verges of contingency]. Ter Arkh 2017;89:59-65. [PMID: 28281517 DOI: 10.17116/terarkh201789259-65] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
365 Phisalprapa P, Supakankunti S, Charatcharoenwitthaya P, Apisarnthanarak P, Charoensak A, Washirasaksiri C, Srivanichakorn W, Chaiyakunapruk N. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. Medicine (Baltimore) 2017;96:e6585. [PMID: 28445256 DOI: 10.1097/MD.0000000000006585] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
366 Arab JP, Hernández-rocha C, Morales C, Vargas JI, Solís N, Pizarro M, Robles C, Sandoval D, Ponthus S, Benítez C, Barrera F, Soza A, Riquelme A, Arrese M. Fragmento sérico de citoqueratina-18 como marcador no invasivo de esteatohepatitis no alcohólica en población chilena. Gastroenterología y Hepatología 2017;40:388-94. [DOI: 10.1016/j.gastrohep.2017.02.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
367 Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017;66:1138-53. [PMID: 28314735 DOI: 10.1136/gutjnl-2017-313884] [Cited by in Crossref: 511] [Cited by in F6Publishing: 489] [Article Influence: 102.2] [Reference Citation Analysis]
368 Guaraldi G, Lonardo A, Maia L, Palella FJ Jr. Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. AIDS 2017;31 Suppl 2:S147-56. [PMID: 28471945 DOI: 10.1097/QAD.0000000000001483] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
369 Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017;71:182-97. [DOI: 10.1016/j.metabol.2017.03.013] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 14.6] [Reference Citation Analysis]
370 Ranjit S, Dvornikov A, Dobrinskikh E, Wang X, Luo Y, Levi M, Gratton E. Measuring the effect of a Western diet on liver tissue architecture by FLIM autofluorescence and harmonic generation microscopy. Biomed Opt Express 2017;8:3143-54. [PMID: 28717559 DOI: 10.1364/BOE.8.003143] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
371 Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J 2017;135:277-95. [DOI: 10.1590/1516-3180.2016.0306311216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
372 Simões e Silva AC, Miranda AS, Rocha NP, Teixeira AL. Renin angiotensin system in liver diseases: Friend or foe? World J Gastroenterol 2017; 23(19): 3396-3406 [PMID: 28596676 DOI: 10.3748/wjg.v23.i19.3396] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 49] [Article Influence: 11.4] [Reference Citation Analysis]
373 Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:936-944. [PMID: 26667191 DOI: 10.1111/jgh.13264] [Cited by in Crossref: 318] [Cited by in F6Publishing: 363] [Article Influence: 63.6] [Reference Citation Analysis]
374 Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol 2017;6:62-72. [PMID: 31646122 DOI: 10.1097/XCE.0000000000000126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
375 Loo SY, Chan WK. Emerging new standard for non-invasive assessment of liver disease mortality in non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr 2017;6:135-7. [PMID: 28503563 DOI: 10.21037/hbsn.2017.03.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
376 Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol 2017; 8(2): 11-26 [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 50] [Article Influence: 13.2] [Reference Citation Analysis]
377 Peters HPF, Schrauwen P, Verhoef P, Byrne CD, Mela DJ, Pfeiffer AFH, Risérus U, Rosendaal FR, Schrauwen-Hinderling V. Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop. J Nutr Sci 2017;6:e15. [PMID: 28630692 DOI: 10.1017/jns.2017.13] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
378 Heidari Z, Gharebaghi A. Prevalence of Non Alcoholic Fatty Liver Disease and its Association with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. J Clin Diagn Res 2017;11:OC04-7. [PMID: 28658824 DOI: 10.7860/JCDR/2017/25931.9823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
379 Herat L, Rudnicka C, Okada Y, Mochizuki S, Schlaich M, Matthews V. The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice. Int J Mol Sci 2017;18:E884. [PMID: 28430139 DOI: 10.3390/ijms18040884] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
380 Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World J Hepatol 2017; 9(11): 533-543 [PMID: 28469809 DOI: 10.4254/wjh.v9.i11.533] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 20.2] [Reference Citation Analysis]
381 Konstantopoulos P, Doulamis IP, Tzani A, Korou ML, Agapitos E, Vlachos IS, Pergialiotis V, Verikokos C, Mastorakos G, Katsilambros NL, Perrea DN. Metabolic effects of Crocus sativus and protective action against non-alcoholic fatty liver disease in diabetic rats. Biomed Rep 2017;6:513-8. [PMID: 28529733 DOI: 10.3892/br.2017.884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
382 Lai LL, Chan WK, Sthaneshwar P, Nik Mustapha NR, Goh KL, Mahadeva S. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease. PLoS One 2017;12:e0174982. [PMID: 28369100 DOI: 10.1371/journal.pone.0174982] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
383 Belemets N, Kobyliak N, Virchenko O, Falalyeyeva T, Olena T, Bodnar P, Savchuk O, Galenova T, Caprnda M, Rodrigo L, Skladany L, Delev D, Opatrilova R, Kruzliak P, Beregova T, Ostapchenko L. Effects of polyphenol compounds melanin on NAFLD/NASH prevention. Biomedicine & Pharmacotherapy 2017;88:267-76. [DOI: 10.1016/j.biopha.2017.01.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
384 Lee SH, Yun SJ, Kim DH, Jo HH, Park YS. Severity of nonalcoholic fatty liver disease on sonography and risk of coronary heart disease: Nafld Severity and Chd Risk. J Clin Ultrasound 2017;45:391-9. [DOI: 10.1002/jcu.22472] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
385 Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, Nguyen MH. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12:e0173499. [PMID: 28346543 DOI: 10.1371/journal.pone.0173499] [Cited by in Crossref: 116] [Cited by in F6Publishing: 131] [Article Influence: 23.2] [Reference Citation Analysis]
386 Wang S, Zhang J, Zhu L, Song L, Meng Z, Jia Q, Li X, Liu N, Hu T, Zhou P, Zhang Q, Liu L, Song K, Jia Q. Association between liver function and metabolic syndrome in Chinese men and women. Sci Rep 2017;7:44844. [PMID: 28317840 DOI: 10.1038/srep44844] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
387 Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol 2017;5:67-75. [PMID: 28507929 DOI: 10.14218/JCTH.2016.00061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
388 Camarena C, Aldamiz-Echevarria LJ, Polo B, Barba Romero MA, García I, Cebolla JJ, Ros E. Update on lysosomal acid lipase deficiency: Diagnosis, treatment and patient management. Med Clin (Barc) 2017;148:429.e1-429.e10. [PMID: 28285817 DOI: 10.1016/j.medcli.2016.12.044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
389 Barros F, Setúbal S, Martinho JM, Ferraz L, Gaudêncio A. CORRELATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND FEATURES OF METABOLIC SYNDROME IN MORBIDLY OBESE PATIENTS IN THE PREOPERATIVE ASSESSMENT FOR BARIATRIC SURGERY. Arq Bras Cir Dig 2016;29:260-3. [PMID: 28076482 DOI: 10.1590/0102-6720201600040011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
390 Musso G, Cassader M, De Michieli F, Paschetta E, Pinach S, Saba F, Bongiovanni D, Framarin L, Berrutti M, Leone N, Corvisieri S, Parente R, Molinaro F, Sircana A, Bo S, Gambino R. MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat. Human Molecular Genetics 2017;26:1747-58. [DOI: 10.1093/hmg/ddw400] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
391 Liang J, Liu F, Wang F, Han T, Jing L, Ma Z, Gao Y. A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. Biomed Res Int 2017;2017:8793278. [PMID: 28349067 DOI: 10.1155/2017/8793278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
392 Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. Hepatology 2017;65:828-35. [PMID: 28035771 DOI: 10.1002/hep.28917] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 12.8] [Reference Citation Analysis]
393 Musso G, Cipolla U, Cassader M, Pinach S, Saba F, De Michieli F, Paschetta E, Bongiovanni D, Framarin L, Leone N, Berrutti M, Rosina F, Corvisieri S, Molinaro F, Sircana A, Gambino R. TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. J Lipid Res 2017;58:1221-9. [PMID: 28242789 DOI: 10.1194/jlr.M075028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
394 Lee J, Yoon K, Ryu S, Chang Y, Kim HR. High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men. PLoS One 2017;12:e0172666. [PMID: 28234943 DOI: 10.1371/journal.pone.0172666] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
395 Khodadoostan M, Zamanidoost M, Shavakhi A, Sanei H, Shahbazi M, Ahmadian M. Effects of Phlebotomy on Liver Enzymes and Histology of Patients with Nonalcoholic Fatty Liver Disease. Adv Biomed Res 2017;6:12. [PMID: 28299304 DOI: 10.4103/2277-9175.200787] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
396 Gabbia D, Dall'Acqua S, Di Gangi IM, Bogialli S, Caputi V, Albertoni L, Marsilio I, Paccagnella N, Carrara M, Giron MC, De Martin S. The Phytocomplex from Fucus vesiculosus and Ascophyllum nodosum Controls Postprandial Plasma Glucose Levels: An In Vitro and In Vivo Study in a Mouse Model of NASH. Mar Drugs 2017;15:E41. [PMID: 28212301 DOI: 10.3390/md15020041] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
397 Yu XY, Li Y, Liu T, Wang RT. Association of whole blood viscosity with non-alcoholic fatty liver disease. Clin Hemorheol Microcirc 2015;62:335-43. [PMID: 26444605 DOI: 10.3233/CH-151974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
398 Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol 2017;2:211-23. [PMID: 28404136 DOI: 10.1016/S2468-1253(16)30120-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
399 Sinn DH, Kang D, Chang Y, Ryu S, Gu S, Kim H, Seong D, Cho SJ, Yi BK, Park HD, Paik SW, Song YB, Lazo M, Lima JA, Guallar E, Cho J, Gwak GY. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut 2017;66:323-9. [PMID: 27599521 DOI: 10.1136/gutjnl-2016-311854] [Cited by in Crossref: 83] [Cited by in F6Publishing: 87] [Article Influence: 16.6] [Reference Citation Analysis]
400 Li R, Guo E, Yang J, Li A, Yang Y, Liu S, Liu A, Jiang X. 1,25(OH)2 D3 attenuates hepatic steatosis by inducing autophagy in mice. Obesity (Silver Spring). 2017;25:561-571. [PMID: 28145056 DOI: 10.1002/oby.21757] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
401 Muangpaisarn P, Jampoka K, Payungporn S, Wisedopas N, Bunchorntavakul C, Tangkijvanich P, Treeprasertsuk S. Serum microRNA-34a is potential biomarker for inflammation in nonalcoholic fatty liver disease. Asian Biomedicine 2017;10:163-71. [DOI: 10.5372/1905-7415.1002.478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
402 Mahady SE, Gale J, Macaskill P, Craig JC, George J. Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: A cross-sectional study of 9,447 people: Elevated alanine transaminase in Australia. Journal of Gastroenterology and Hepatology 2017;32:169-76. [DOI: 10.1111/jgh.13434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
403 Reyes-garcía R, Rozas-moreno P, Llamoza-torres CJ, Mezquita-raya P. Hígado graso no alcohólico y diabetes. Medicina Clínica 2017;148:33-8. [DOI: 10.1016/j.medcli.2016.08.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
404 Stättermayer AF, Traussnigg S, Aigner E, Kienbacher C, Huber-schönauer U, Steindl-munda P, Stadlmayr A, Wrba F, Trauner M, Datz C, Ferenci P. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. Journal of Trace Elements in Medicine and Biology 2017;39:100-7. [DOI: 10.1016/j.jtemb.2016.08.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
405 Mazzotti A, Caletti MT, Marchignoli F, Forlani G, Marchesini G. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? Dig Liver Dis 2017;49:235-40. [PMID: 28089623 DOI: 10.1016/j.dld.2016.12.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
406 Du X, Cai C, Yao J, Zhou Y, Yu H, Shen W. Histone modifications in FASN modulated by sterol regulatory element-binding protein 1c and carbohydrate responsive-element binding protein under insulin stimulation are related to NAFLD. Biochem Biophys Res Commun 2017;483:409-17. [PMID: 28027934 DOI: 10.1016/j.bbrc.2016.12.129] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
407 Lykiardopoulos B, Hagström H, Fredrikson M, Ignatova S, Stål P, Hultcrantz R, Ekstedt M, Kechagias S. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. PLoS One 2016;11:e0167776. [PMID: 27936091 DOI: 10.1371/journal.pone.0167776] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
408 Lelouvier B, Servant F, Païssé S, Brunet AC, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, Federici M, Fernández-Real JM, Burcelin R, Amar J. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. Hepatology 2016;64:2015-27. [PMID: 27639192 DOI: 10.1002/hep.28829] [Cited by in Crossref: 147] [Cited by in F6Publishing: 144] [Article Influence: 24.5] [Reference Citation Analysis]
409 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 77] [Article Influence: 12.8] [Reference Citation Analysis]
410 Ahn JS, Sinn DH, Min YW, Hong SN, Kim HS, Jung S, Gu S, Rhee P, Paik SW, Son HJ, Gwak G. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther 2017;45:345-53. [DOI: 10.1111/apt.13866] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
411 Xu ZJ, Shi JP, Yu DR, Zhu LJ, Jia JD, Fan JG. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design. Adv Ther 2016;33:2069-81. [PMID: 27743352 DOI: 10.1007/s12325-016-0416-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
412 Mazzolini G, Sowa J, Canbay A. Cell death mechanisms in human chronic liver diseases: a far cry from clinical applicability. Clinical Science 2016;130:2121-38. [DOI: 10.1042/cs20160035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
413 Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015;16:541-57. [PMID: 26406351 DOI: 10.1111/1751-2980.12291] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 9.7] [Reference Citation Analysis]
414 Odena G, Chen J, Lozano JJ, Altamirano J, Rodrigo-Torres D, Affo S, Morales-Ibanez O, Matsushita H, Zou J, Dumitru R, Caballeria J, Gines P, Arroyo V, You M, Rautou PE, Valla D, Crews F, Seki E, Sancho-Bru P, Bataller R. LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. Sci Rep 2016;6:35610. [PMID: 27752144 DOI: 10.1038/srep35610] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
415 Ma J, Hwang SJ, Pedley A, Massaro JM, Hoffmann U, Chung RT, Benjamin EJ, Levy D, Fox CS, Long MT. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66:390-397. [PMID: 27729222 DOI: 10.1016/j.jhep.2016.09.022] [Cited by in Crossref: 65] [Cited by in F6Publishing: 79] [Article Influence: 10.8] [Reference Citation Analysis]
416 Simon TG, Corey KE, Chung RT, Giugliano R. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci 2016;61:3425-35. [DOI: 10.1007/s10620-016-4330-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
417 Almeda-valdes P, Aguilar-salinas CA, Uribe M, Canizales-quinteros S, Méndez-sánchez N. Impact of anthropometric cut-off values in determining the prevalence of metabolic alterations. Eur J Clin Invest 2016;46:940-6. [DOI: 10.1111/eci.12672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
418 Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H, Targher G. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:1388-9. [PMID: 27038241 DOI: 10.1002/hep.28584] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 9.7] [Reference Citation Analysis]
419 Zhang H, Shen WJ, Li Y, Bittner A, Bittner S, Tabassum J, Cortez YF, Kraemer FB, Azhar S. Microarray analysis of gene expression in liver, adipose tissue and skeletal muscle in response to chronic dietary administration of NDGA to high-fructose fed dyslipidemic rats. Nutr Metab (Lond) 2016;13:63. [PMID: 27708683 DOI: 10.1186/s12986-016-0121-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
420 Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:23-31. [PMID: 26111358 DOI: 10.1111/jgh.13026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
421 Fierbinteanu-Braticevici C, Sinescu C, Moldoveanu A, Petrisor A, Diaconu S, Cretoiu D, Braticevici B. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health. Cell Biol Toxicol 2017;33:5-14. [PMID: 27680752 DOI: 10.1007/s10565-016-9361-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
422 Brea Á, Pintó X, Ascaso JF, Blasco M, Díaz Á, González-Santos P, Hernández Mijares A, Mantilla T, Millán J, Pedro-Botet J; Grupo de trabajo sobre Dislipemia Aterogénica. Sociedad Española de Arteriosclerosis. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease. Clin Investig Arterioscler 2017;29:141-8. [PMID: 27692633 DOI: 10.1016/j.arteri.2016.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
423 Elkabbany ZA, Elbarbary NS, Ismail EA, Mohamed NA, Ragab D, Abdel Alem S, Ezzat YM, Maurice SS, Hashem NU. Transient elastography as a noninvasive assessment tool for hepatopathies of different etiology in pediatric type 1 diabetes mellitus. J Diabetes Complications 2017;31:186-94. [PMID: 27742550 DOI: 10.1016/j.jdiacomp.2016.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
424 Rowell RJ, Anstee QM. An overview of the genetics, mechanisms and management of NAFLD and ALD. Clin Med (Lond). 2015;15 Suppl 6:s77-s82. [PMID: 26634687 DOI: 10.7861/clinmedicine.15-6-s77] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
425 Jaruvongvanich V, Wirunsawanya K, Sanguankeo A, Upala S. Nonalcoholic fatty liver disease is associated with coronary artery calcification: A systematic review and meta-analysis. Dig Liver Dis 2016;48:1410-7. [PMID: 27697419 DOI: 10.1016/j.dld.2016.09.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
426 Degasperi E, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2016;1:156-164. [PMID: 28404072 DOI: 10.1016/s2468-1253(16)30018-8] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 12.3] [Reference Citation Analysis]
427 Zhang Z, Wang G, Kang K, Wu G, Wang P. Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection. Sci Rep 2016;6:32875. [PMID: 27597515 DOI: 10.1038/srep32875] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
428 Mehta R, Jeiran K, Koenig AB, Otgonsuren M, Goodman Z, Baranova A, Younossi Z. The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). BMC Med Genet 2016;17:63. [PMID: 27596100 DOI: 10.1186/s12881-016-0324-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
429 Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, Lee KL, Kim W. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66:123-131. [PMID: 27599824 DOI: 10.1016/j.jhep.2016.08.019] [Cited by in Crossref: 163] [Cited by in F6Publishing: 205] [Article Influence: 27.2] [Reference Citation Analysis]
430 Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. Journal of Hepatology 2016;65:589-600. [DOI: 10.1016/j.jhep.2016.05.013] [Cited by in Crossref: 515] [Cited by in F6Publishing: 611] [Article Influence: 85.8] [Reference Citation Analysis]
431 Boursier J, Vergniol J, Guillet A, Hiriart J, Lannes A, Le Bail B, Michalak S, Chermak F, Bertrais S, Foucher J, Oberti F, Charbonnier M, Fouchard-hubert I, Rousselet M, Calès P, de Lédinghen V. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. Journal of Hepatology 2016;65:570-8. [DOI: 10.1016/j.jhep.2016.04.023] [Cited by in Crossref: 183] [Cited by in F6Publishing: 196] [Article Influence: 30.5] [Reference Citation Analysis]
432 Kim D, Kim WR. Nonobese Fatty Liver Disease. Clin Gastroenterol Hepatol. 2017;15:474-485. [PMID: 27581063 DOI: 10.1016/j.cgh.2016.08.028] [Cited by in Crossref: 191] [Cited by in F6Publishing: 178] [Article Influence: 31.8] [Reference Citation Analysis]
433 Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol 2016; 22(32): 7236-7251 [PMID: 27621571 DOI: 10.3748/wjg.v22.i32.7236] [Cited by in CrossRef: 128] [Cited by in F6Publishing: 124] [Article Influence: 21.3] [Reference Citation Analysis]
434 Ha Y, Seo N, Shim JH, Kim SY, Park JA, Han S, Kim KW, Yu E, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study. J Gastroenterol Hepatol. 2015;30:1666-1672. [PMID: 25974139 DOI: 10.1111/jgh.12996] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
435 Canbay A, Gerken G, Bechmann LP. [Hepatic steatosis : Differential diagnostics and current aspects]. Internist (Berl) 2016;57:879-92. [PMID: 27510334 DOI: 10.1007/s00108-016-0112-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
436 Jung JY, Park SK, Ryoo J, Oh C, Kang JG, Lee J, Choi J. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population: NAFLD, left ventricular diastolic dysfunction. Hepatol Res 2017;47:522-32. [DOI: 10.1111/hepr.12770] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
437 Musso G, De Michieli F, Bongiovanni D, Parente R, Framarin L, Leone N, Berrutti M, Gambino R, Cassader M, Cohney S, Paschetta E. New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease. Clin Gastroenterol Hepatol 2017;15:972-85. [PMID: 27521506 DOI: 10.1016/j.cgh.2016.08.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
438 Xanthakos SA. Noninvasive Assessment of Nonalcoholic Steatohepatitis and Nonalcoholic Steatohepatitis-Related Fibrosis: Is There a Role for Cytokeratin 18? Journal of Pediatric Gastroenterology & Nutrition 2016;63:167-8. [DOI: 10.1097/mpg.0000000000001193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
439 Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 2016;65:1136-50. [DOI: 10.1016/j.metabol.2015.09.017] [Cited by in Crossref: 152] [Cited by in F6Publishing: 144] [Article Influence: 25.3] [Reference Citation Analysis]
440 Chang Y, Jung H, Yun KE, Cho J, Ahn J, Chung EC, Shin H, Ryu S. Metabolically healthy obesity is associated with an increased risk of diabetes independently of nonalcoholic fatty liver disease: Obesity, Fatty Liver, and Incident Diabetes. Obesity 2016;24:1996-2003. [DOI: 10.1002/oby.21580] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
441 Satapathy SK, Kuwajima V, Nadelson J, Atiq O, Sanyal AJ. Drug-induced fatty liver disease: An overview of pathogenesis and management. Ann Hepatol 2015;14:789-806. [PMID: 26436351 DOI: 10.5604/16652681.1171749] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
442 Pallotta N, Filardi T, Carnovale A, Nieddu L, Mariani P, Vincoli G, Lenzi A, Morano S. Two-hour postload glycemia is associated to an increased risk of NAFLD in healthy subjects with family history of type 2 diabetes: a case control study. Endocrine 2017;57:352-5. [PMID: 27422790 DOI: 10.1007/s12020-016-1008-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
443 Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends Mol Med. 2015;21:645-662. [PMID: 26432021 DOI: 10.1016/j.molmed.2015.08.005] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 9.3] [Reference Citation Analysis]
444 Fallatah HI, Akbar HO, Fallatah AM. Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease. Hepat Mon 2016;16:e38346. [PMID: 27642348 DOI: 10.5812/hepatmon.38346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
445 Karahashi M, Hirata-Hanta Y, Kawabata K, Tsutsumi D, Kametani M, Takamatsu N, Sakamoto T, Yamazaki T, Asano S, Mitsumoto A, Kawashima Y, Kudo N. Abnormalities in the Metabolism of Fatty Acids and Triacylglycerols in the Liver of the Goto-Kakizaki Rat: A Model for Non-Obese Type 2 Diabetes. Lipids 2016;51:955-71. [PMID: 27372943 DOI: 10.1007/s11745-016-4171-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
446 Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-pollack R, Plodkowski R. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines Formedical Care of Patients with Obesity. Endocrine Practice 2016;22:1-203. [DOI: 10.4158/ep161365.gl] [Cited by in Crossref: 406] [Cited by in F6Publishing: 476] [Article Influence: 67.7] [Reference Citation Analysis]
447 Chan WK, Nik Mustapha NR, Wong GL, Wong VW, Mahadeva S. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. United European Gastroenterol J 2017;5:76-85. [PMID: 28405325 DOI: 10.1177/2050640616646528] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
448 Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci 2016;17:E947. [PMID: 27314342 DOI: 10.3390/ijms17060947] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 12.8] [Reference Citation Analysis]
449 Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Villa-Jimenez O, Friedman SL, Diago M, Romero-Gomez M. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology 2016;63:1875-87. [PMID: 26849287 DOI: 10.1002/hep.28484] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
450 Pan H, Chang H, Lee C. Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients. Journal of the Formosan Medical Association 2016;115:411-7. [DOI: 10.1016/j.jfma.2015.05.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
451 Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65:425-443. [PMID: 27091791 DOI: 10.1016/j.jhep.2016.04.005] [Cited by in Crossref: 190] [Cited by in F6Publishing: 230] [Article Influence: 31.7] [Reference Citation Analysis]
452 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol. 2016;7:211-217. [PMID: 27190693 DOI: 10.3349/ymj.2016.57.4.885] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
453 Chang Y, Jung HS, Cho J, Zhang Y, Yun KE, Lazo M, Pastor-Barriuso R, Ahn J, Kim CW, Rampal S. Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016;111:1133-1140. [PMID: 27185080 DOI: 10.1038/ajg.2016.178] [Cited by in Crossref: 91] [Cited by in F6Publishing: 108] [Article Influence: 15.2] [Reference Citation Analysis]
454 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016; 7(2): 211-217 [PMID: 27190693 DOI: 10.4291/wjgp.v7.i2.211] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 50] [Article Influence: 8.7] [Reference Citation Analysis]
455 Sanna C, Rosso C, Marietti M, Bugianesi E. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. Int J Mol Sci. 2016;17:pii: E717. [PMID: 27187365 DOI: 10.3390/ijms17050717] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 15.5] [Reference Citation Analysis]
456 Zhang ZQ, Wang GS, Kang KF, Wu GB, Wang P. Nomogram for hepatic steatosis: A simple and economical diagnostic tool for massive screening. Dig Liver Dis 2016;48:914-20. [PMID: 27246795 DOI: 10.1016/j.dld.2016.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
457 Mlynarsky L, Schlesinger D, Lotan R, Webb M, Halpern Z, Santo E, Shibolet O, Zelber-Sagi S. Non-alcoholic fatty liver disease is not associated with a lower health perception. World J Gastroenterol 2016; 22(17): 4362-4372 [PMID: 27158205 DOI: 10.3748/wjg.v22.i17.4362] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
458 Vespasiani-Gentilucci U, Gallo P, Porcari A, Carotti S, Galati G, Piccioni L, De Vincentis A, Dell'Unto C, Vorini F, Morini S, Riva E, Picardi A. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand J Gastroenterol 2016;51:967-73. [PMID: 27150500 DOI: 10.3109/00365521.2016.1161066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
459 Targher G, Marchesini G, Byrne CD. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? Diabetes Metab. 2016;42:142-156. [PMID: 27142870 DOI: 10.1016/j.diabet.2016.04.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
460 Yan LH, Mu B, Guan Y, Liu X, Zhao N, Pan D, Wang SZ. Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications. J Diabetes Investig 2016;7:889-94. [PMID: 27181828 DOI: 10.1111/jdi.12518] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
461 Villela-Nogueira CA, Leite NC, Cardoso CR, Salles GF. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms? Int J Mol Sci 2016;17:E460. [PMID: 27104526 DOI: 10.3390/ijms17040460] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
462 Forlani G, Giorda C, Manti R, Mazzella N, De Cosmo S, Rossi MC, Nicolucci A, Di Bartolo P, Ceriello A, Guida P; AMD-Annals Study Group. The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes. J Diabetes Res 2016;2016:2931985. [PMID: 27123461 DOI: 10.1155/2016/2931985] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 6.5] [Reference Citation Analysis]
463 Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46:1074-1087. [PMID: 26785389 DOI: 10.1111/hepr.12656] [Cited by in Crossref: 74] [Cited by in F6Publishing: 94] [Article Influence: 12.3] [Reference Citation Analysis]
464 VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016;15:75-85. [PMID: 27218012 DOI: 10.1007/s11901-016-0295-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 9.5] [Reference Citation Analysis]
465 Goh GB, McCullough AJ. Natural History of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016;61:1226-33. [PMID: 27003142 DOI: 10.1007/s10620-016-4095-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 71] [Article Influence: 14.5] [Reference Citation Analysis]
466 Arısoy A, Sertoğullarından B, Ekin S, Özgökçe M, Bulut MD, Huyut MT, Ölmez Ş, Turan M. Sleep Apnea and Fatty Liver Are Coupled Via Energy Metabolism. Med Sci Monit 2016;22:908-13. [PMID: 26993969 DOI: 10.12659/msm.898214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
467 Bedossa P, Patel K. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1811-1822.e4. [PMID: 27003601 DOI: 10.1053/j.gastro.2016.03.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 10.7] [Reference Citation Analysis]
468 Kobyliak N, Falalyeyeva T, Virchenko O, Mykhalchyshyn G, Bodnar P, Spivak M, Yankovsky D, Beregova T, Ostapchenko L. Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention. BMC Gastroenterol. 2016;16:34. [PMID: 26976285 DOI: 10.1186/s12876-016-0451-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
469 García Díaz E, Guagnozzi D, Gutiérrez V, Mendoza C, Maza C, Larrañaga Y, Perdomo D, Godoy T, Taleb G. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. Endocrinol Nutr 2016;63:194-201. [PMID: 26976710 DOI: 10.1016/j.endonu.2016.01.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
470 Wainwright P, Byrne CD. Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. Int J Mol Sci. 2016;17:367. [PMID: 26978356 DOI: 10.3390/ijms17030367] [Cited by in Crossref: 57] [Cited by in F6Publishing: 68] [Article Influence: 9.5] [Reference Citation Analysis]
471 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
472 Corey KE, Rinella ME. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci 2016;61:1387-97. [PMID: 26942734 DOI: 10.1007/s10620-016-4083-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
473 Khan RS, Newsome PN. Non-alcoholic fatty liver disease and liver transplantation. Metabolism. 2016;65:1208-1223. [PMID: 26997540 DOI: 10.1016/j.metabol.2016.02.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
474 Zhan YT, Su HY, An W. Glycosyltransferases and non-alcoholic fatty liver disease. World J Gastroenterol 2016; 22(8): 2483-2493 [PMID: 26937136 DOI: 10.3748/wjg.v22.i8.2483] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
475 Machado MV, Diehl AM. Pathogenesis of Nonalcoholic Steatohepatitis. Gastroenterology 2016;150:1769-77. [PMID: 26928243 DOI: 10.1053/j.gastro.2016.02.066] [Cited by in Crossref: 169] [Cited by in F6Publishing: 210] [Article Influence: 28.2] [Reference Citation Analysis]
476 Tula E, Ergun T, Seckin D, Ozgen Z, Avsar E. Psoriasis and the liver: problems, causes and course. Australas J Dermatol 2017;58:194-9. [PMID: 26916498 DOI: 10.1111/ajd.12460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
477 Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13:196-205. [PMID: 26907882 DOI: 10.1038/nrgastro.2016.3] [Cited by in Crossref: 186] [Cited by in F6Publishing: 174] [Article Influence: 31.0] [Reference Citation Analysis]
478 Benotti P, Wood GC, Argyropoulos G, Pack A, Keenan BT, Gao X, Gerhard G, Still C. The impact of obstructive sleep apnea on nonalcoholic fatty liver disease in patients with severe obesity. Obesity (Silver Spring). 2016;24:871-877. [PMID: 26880657 DOI: 10.1002/oby.21409] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
479 Anstee QM, Seth D, Day CP. Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1728-1744.e7. [PMID: 26873399 DOI: 10.1053/j.gastro.2016.01.037] [Cited by in Crossref: 121] [Cited by in F6Publishing: 129] [Article Influence: 20.2] [Reference Citation Analysis]
480 Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-S64. [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012] [Cited by in Crossref: 1011] [Cited by in F6Publishing: 1240] [Article Influence: 168.5] [Reference Citation Analysis]
481 Siculella L, Tocci R, Rochira A, Testini M, Gnoni A, Damiano F. Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis. Biochim Biophys Acta 2016;1861:471-81. [PMID: 26869449 DOI: 10.1016/j.bbalip.2016.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
482 Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism. 2016;65:1087-1095. [PMID: 26972222 DOI: 10.1016/j.metabol.2016.01.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
483 Kumar R, Boon-Bee Goh G. Chronic hepatitis B and fatty liver: Issues in clinical management. Clin Res Hepatol Gastroenterol 2016;40:755-9. [PMID: 26850361 DOI: 10.1016/j.clinre.2015.12.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
484 Yoshimura K, Okanoue T, Ebise H, Iwasaki T, Mizuno M, Shima T, Ichihara J, Yamazaki K. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology 2016;63:462-73. [PMID: 26390046 DOI: 10.1002/hep.28226] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
485 Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci 2016;61:2108-17. [PMID: 26825843 DOI: 10.1007/s10620-016-4044-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
486 Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017-1025. [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012] [Cited by in Crossref: 238] [Cited by in F6Publishing: 212] [Article Influence: 39.7] [Reference Citation Analysis]
487 Valva P, Ríos DA, De Matteo E, Preciado MV. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol 2016; 22(4): 1367-1381 [PMID: 26819506 DOI: 10.3748/wjg.v22.i4.1367] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
488 Patterson RE, Kalavalapalli S, Williams CM, Nautiyal M, Mathew JT, Martinez J, Reinhard MK, McDougall DJ, Rocca JR, Yost RA, Cusi K, Garrett TJ, Sunny NE. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. Am J Physiol Endocrinol Metab. 2016;310:E484-E494. [PMID: 26814015 DOI: 10.1152/ajpendo.00492.2015] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 15.8] [Reference Citation Analysis]
489 Mantovani A, Ballestri S, Lonardo A, Targher G. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1246-1267. [PMID: 26809873 DOI: 10.1007/s10620-016-4040-6] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 12.2] [Reference Citation Analysis]
490 Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Hepat Mon. 2016;16:e34897. [PMID: 27110262 DOI: 10.5812/hepatmon.34897] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 6.8] [Reference Citation Analysis]
491 Silaghi CA, Silaghi H, Colosi HA, Craciun AE, Farcas A, Cosma DT, Hancu N, Pais R, Georgescu CE. Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population. Clujul Med 2016;89:82-8. [PMID: 27004029 DOI: 10.15386/cjmed-544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
492 Kimura T, Deshpande GA, Urayama KY, Masuda K, Fukui T, Matsuyama Y. Association of weight gain since age 20 with non-alcoholic fatty liver disease in normal weight individuals. J Gastroenterol Hepatol 2015;30:909-17. [PMID: 25469977 DOI: 10.1111/jgh.12861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
493 Zhang L, You W, Zhang H, Peng R, Zhu Q, Yao A, Li X, Zhou Y, Wang X, Pu L, Wu J. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. J Gastroenterol Hepatol. 2015;30:821-829. [PMID: 25641744 DOI: 10.1111/jgh.12889] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 6.2] [Reference Citation Analysis]
494 Keramida G, Hunter J, Dizdarevic S, Peters AM. Heterogeneity of intrahepatic fat distribution determined by 18F-FDG PET and CT. Ann Nucl Med 2016;30:200-6. [DOI: 10.1007/s12149-015-1045-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
495 Stankovic Z. Four-dimensional flow magnetic resonance imaging in cirrhosis. World J Gastroenterol 2016; 22(1): 89-102 [PMID: 26755862 DOI: 10.3748/wjg.v22.i1.89] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
496 Le Corvec M, Allain C, Lardjane S, Cavey T, Turlin B, Fautrel A, Begriche K, Monbet V, Fromenty B, Leroyer P, Guggenbuhl P, Ropert M, Sire O, Loréal O. Mid-infrared fibre evanescent wave spectroscopy of serum allows fingerprinting of the hepatic metabolic status in mice. Analyst 2016;141:6259-69. [DOI: 10.1039/c6an00136j] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
497 Xu H, Hsu Y, Chang C, Wei K, Lin C. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease. Hepatol Int 2016;10:340-6. [DOI: 10.1007/s12072-015-9690-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
498 Lee HJ, Yeon JE, Ko EJ, Yoon EL, Suh SJ, Kang K, Kim HR, Kang SH, Yoo YJ, Je J, Lee BJ, Kim JH, Seo YS, Yim HJ, Byun KS. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(45): 12787-12799 [PMID: 26668503 DOI: 10.3748/wjg.v21.i45.12787] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
499 Williams KH, Sullivan DR, Veillard AS, O'brien R, George J, Jenkins AJ, Young S, Ehnholm C, Duffield A, Twigg SM, Keech AC. Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabet Med 2016;33:356-64. [DOI: 10.1111/dme.12972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
500 Asrih M, Jornayvaz FR. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Molecular and Cellular Endocrinology 2015;418:55-65. [DOI: 10.1016/j.mce.2015.02.018] [Cited by in Crossref: 150] [Cited by in F6Publishing: 174] [Article Influence: 21.4] [Reference Citation Analysis]
501 Coppell KJ, Miller JC, Gray AR, Schultz M, Mann JI, Parnell WR. Obesity and the extent of liver damage among adult New Zealanders: findings from a national survey. Obes Sci Pract 2015;1:67-77. [PMID: 27774250 DOI: 10.1002/osp4.13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
502 Mishra AK, Dubey V, Ghosh AR. Obesity: An overview of possible role(s) of gut hormones, lipid sensing and gut microbiota. Metabolism. 2016;65:48-65. [PMID: 26683796 DOI: 10.1016/j.metabol.2015.10.008] [Cited by in Crossref: 89] [Cited by in F6Publishing: 81] [Article Influence: 12.7] [Reference Citation Analysis]
503 Puchakayala BK, Verma S, Kanwar P, Hart J, Sanivarapu RR, Mohanty SR. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World J Hepatol 2015; 7(25): 2610-2618 [PMID: 26557954 DOI: 10.4254/wjh.v7.i25.2610] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
504 Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2016;30:282-287. [PMID: 26537011 DOI: 10.1111/jdv.13456] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
505 Corey KE, Kartoun U, Zheng H, Shaw SY. Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical Record. Dig Dis Sci. 2016;61:913-919. [PMID: 26537487 DOI: 10.1007/s10620-015-3952-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
506 Kawanaka M, Nishino K, Nakamura J, Urata N, Oka T, Goto D, Suehiro M, Kawamoto H, Yamada G. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease. Annals of Hepatology 2015;14:837-44. [DOI: 10.5604/16652681.1171767] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
507 Losekann A, Weston AC, de Mattos AA, Tovo CV, de Carli LA, Espindola MB, Pioner SR, Coral GP. Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients. Int J Mol Sci. 2015;16:25552-25559. [PMID: 26512661 DOI: 10.3390/ijms161025552] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
508 Stål P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol 2015; 21(39): 11077-11087 [PMID: 26494963 DOI: 10.3748/wjg.v21.i39.11077] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 83] [Article Influence: 12.9] [Reference Citation Analysis]
509 Macaluso FS, Maida M, Petta S. Genetic background in nonalcoholic fatty liver disease: A comprehensive review. World J Gastroenterol 2015; 21(39): 11088-11111 [PMID: 26494964 DOI: 10.3748/wjg.v21.i39.11088] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
510 Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. 2016;10:63-71. [PMID: 26469309 DOI: 10.1586/17474124.2016.1099433] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
511 Nobili V, Alisi A, Musso G, Scorletti E, Calder PC, Byrne CD. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Crit Rev Clin Lab Sci. 2016;53:106-120. [PMID: 26463349 DOI: 10.3109/10408363.2015.1092106] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
512 Goh GB, Kwan C, Lim SY, Venkatanarasimha NK, Abu-Bakar R, Krishnamoorthy TL, Shim HH, Tay KH, Chow WC. Perceptions of non-alcoholic fatty liver disease - an Asian community-based study. Gastroenterol Rep (Oxf). 2016;4:131-135. [PMID: 26463276 DOI: 10.1093/gastro/gov047] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
513 Chan WK, Ida NH, Cheah PL, Goh KL. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study. J Dig Dis. 2014;15:545-552. [PMID: 25060399 DOI: 10.1111/1751-2980.12175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
514 Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab 2015;19:597-601. [PMID: 26425466 DOI: 10.4103/2230-8210.163172] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
515 Rosso C, Caviglia GP, Abate ML, Vanni E, Mezzabotta L, Touscoz GA, Olivero A, Marengo A, Rizzetto M, Bugianesi E, Smedile A. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. Dig Liver Dis 2016;48:55-61. [PMID: 26514735 DOI: 10.1016/j.dld.2015.09.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
516 Popov VB, Lim JK. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. J Clin Transl Hepatol. 2015;3:230-238. [PMID: 26623270 DOI: 10.14218/jcth.2015.00019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
517 Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43:83-95. [PMID: 26369383 DOI: 10.1111/apt.13405] [Cited by in Crossref: 131] [Cited by in F6Publishing: 110] [Article Influence: 18.7] [Reference Citation Analysis]
518 VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, Lewis CE, Rinella ME, Shah SJ. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 2015;62:773-83. [PMID: 25914296 DOI: 10.1002/hep.27869] [Cited by in Crossref: 156] [Cited by in F6Publishing: 144] [Article Influence: 22.3] [Reference Citation Analysis]
519 Hwang H, Jung TW, Hong HC, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH, Yoo HJ. LECT2 induces atherosclerotic inflammatory reaction via CD209 receptor-mediated JNK phosphorylation in human endothelial cells. Metabolism 2015;64:1175-82. [DOI: 10.1016/j.metabol.2015.06.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
520 Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D, Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L. Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology 2015;63:705-12. [DOI: 10.1016/j.jhep.2015.05.006] [Cited by in Crossref: 195] [Cited by in F6Publishing: 212] [Article Influence: 27.9] [Reference Citation Analysis]
521 Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47:997-1006. [PMID: 26454786 DOI: 10.1016/j.dld.2015.08.004] [Cited by in Crossref: 294] [Cited by in F6Publishing: 267] [Article Influence: 42.0] [Reference Citation Analysis]
522 Peng TC, Kao TW, Wu LW, Chen YJ, Chang YW, Wang CC, Tsao YT, Chen WL. Association Between Pulmonary Function and Nonalcoholic Fatty Liver Disease in the NHANES III Study. Medicine (Baltimore) 2015;94:e907. [PMID: 26020401 DOI: 10.1097/MD.0000000000000907] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
523 Bedossa P, Patel K, Castera L. Histologic and noninvasive estimates of liver fibrosis. Clin Liver Dis (Hoboken). 2015;6:5-8. [PMID: 31040975 DOI: 10.1002/cld.481] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
524 Asrani SK. Incorporation of Noninvasive Measures of Liver Fibrosis Into Clinical Practice: Diagnosis and Prognosis. Clin Gastroenterol Hepatol 2015;13:2190-204. [PMID: 26226095 DOI: 10.1016/j.cgh.2015.07.030] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
525 Williams KH, Burns K, Constantino M, Shackel NA, Prakoso E, Wong J, Wu T, George J, McCaughan GW, Twigg SM. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes.J Diabetes Complications. 2015;29:1240-1247. [PMID: 26297218 DOI: 10.1016/j.jdiacomp.2015.06.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
526 Roeters van Lennep J, Averna M, Alonso R. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. Journal of Clinical Lipidology 2015;9:607-17. [DOI: 10.1016/j.jacl.2015.05.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
527 Liu H, Fu J, Hong R, Liu L, Li F. Acoustic Radiation Force Impulse Elastography for the Non-Invasive Evaluation of Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review & Meta-Analysis. PLoS One. 2015;10:e0127782. [PMID: 26131717 DOI: 10.1371/journal.pone.0127782] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 9.1] [Reference Citation Analysis]
528 Møller S, Bendtsen F. Cardiovascular complications of NAFLD—they do matter. Nat Rev Gastroenterol Hepatol 2015;12:434-6. [DOI: 10.1038/nrgastro.2015.110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
529 Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M. Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(24): 7427-7435 [PMID: 26139988 DOI: 10.3748/wjg.v21.i24.7427] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
530 Fabbrini E, Magkos F. Hepatic Steatosis as a Marker of Metabolic Dysfunction. Nutrients 2015;7:4995-5019. [PMID: 26102213 DOI: 10.3390/nu7064995] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 12.9] [Reference Citation Analysis]
531 Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21(22): 6820-6834 [PMID: 26078558 DOI: 10.3748/wjg.v21.i22.6820] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 91] [Article Influence: 14.4] [Reference Citation Analysis]
532 Nobili V, Alisi A, Cutrera R, Carpino G, De Stefanis C, D'Oria V, De Vito R, Cucchiara S, Gaudio E, Musso G. Altered gut-liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver. Thorax 2015;70:769-81. [PMID: 26069285 DOI: 10.1136/thoraxjnl-2015-206782] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
533 Ortiz-Avila O, Gallegos-Corona MA, Sánchez-Briones LA, Calderón-Cortés E, Montoya-Pérez R, Rodriguez-Orozco AR, Campos-García J, Saavedra-Molina A, Mejía-Zepeda R, Cortés-Rojo C. Protective effects of dietary avocado oil on impaired electron transport chain function and exacerbated oxidative stress in liver mitochondria from diabetic rats. J Bioenerg Biomembr 2015;47:337-53. [PMID: 26060181 DOI: 10.1007/s10863-015-9614-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
534 Radmard AR, Poustchi H, Dadgostar M, Yoonessi A, Kooraki S, Jafari E, Hashemi Taheri AP, Malekzadeh R, Merat S. Liver enzyme levels and hepatic iron content in Fatty liver: a noninvasive assessment in general population by T2* mapping. Acad Radiol 2015;22:714-21. [PMID: 25754799 DOI: 10.1016/j.acra.2015.01.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
535 Alkhouri N, Kheirandish-Gozal L, Matloob A, Alonso-Álvarez ML, Khalyfa A, Terán-Santos J, Okwu V, Lopez R, Gileles-Hillel A, Dweik R, Gozal D. Evaluation of circulating markers of hepatic apoptosis and inflammation in obese children with and without obstructive sleep apnea. Sleep Med 2015;16:1031-5. [PMID: 26298775 DOI: 10.1016/j.sleep.2015.05.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
536 Lückhoff HK, Kruger FC, Kotze MJ. Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol 2015; 7(9): 1192-1208 [PMID: 26019735 DOI: 10.4254/wjh.v7.i9.1192] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
537 Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr. 2015;4:101-108. [PMID: 26005676 DOI: 10.3978/j.issn.2304-3881.2015.01.03] [Cited by in F6Publishing: 66] [Reference Citation Analysis]
538 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25:3282-3294. [PMID: 25994191 DOI: 10.1007/s00330-015-3731-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
539 Festi D, Schiumerini R, Marasco G, Scaioli E, Pasqui F, Colecchia A. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology & Hepatology 2015;9:1039-53. [DOI: 10.1586/17474124.2015.1049155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
540 Mykhalchyshyn G, Kobyliak N, Bodnar P. Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Metab Disord. 2015;14:44. [PMID: 25995986 DOI: 10.1186/s40200-015-0170-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
541 Urushima H, Sanada Y, Sakaue M, Matsuzawa Y, Ito T, Maeda K. Maltitol Prevents the Progression of Fatty Liver Degeneration in Mice Fed High-Fat Diets. J Med Food 2015;18:1081-7. [PMID: 26061453 DOI: 10.1089/jmf.2014.3380] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
542 Chen Y, Xu M, Wang T, Sun J, Sun W, Xu B, Huang X, Xu Y, Lu J, Li X, Wang W, Bi Y, Ning G. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis. 2015;241:145-150. [PMID: 25988358 DOI: 10.1016/j.atherosclerosis.2015.05.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
543 Jin R, Le NA, Cleeton R, Sun X, Cruz Muños J, Otvos J, Vos MB. Amount of hepatic fat predicts cardiovascular risk independent of insulin resistance among Hispanic-American adolescents. Lipids Health Dis 2015;14:39. [PMID: 25925168 DOI: 10.1186/s12944-015-0038-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
544 Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54. [PMID: 25125077 DOI: 10.1002/hep.27368] [Cited by in Crossref: 1190] [Cited by in F6Publishing: 1115] [Article Influence: 170.0] [Reference Citation Analysis]
545 Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Int J Endocrinol 2015;2015:343828. [PMID: 26064107 DOI: 10.1155/2015/343828] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
546 Kwak M, Kim D. Long-Term Outcomes of Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2015;14:69-76. [DOI: 10.1007/s11901-015-0258-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
547 Arulanandan A, Loomba R. Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Curr Hepatol Rep 2015;14:109-18. [PMID: 26500833 DOI: 10.1007/s11901-015-0263-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
548 European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 918] [Cited by in F6Publishing: 940] [Article Influence: 131.1] [Reference Citation Analysis]
549 Koplay M, Sivri M, Erdogan H, Nayman A. Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease. World J Hepatol 2015; 7(5): 769-776 [PMID: 25914777 DOI: 10.4254/wjh.v7.i5.769] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
550 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149:367-78.e5; quiz e14. [PMID: 25865049 DOI: 10.1053/j.gastro.2015.04.005] [Cited by in Crossref: 807] [Cited by in F6Publishing: 920] [Article Influence: 115.3] [Reference Citation Analysis]
551 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 118] [Article Influence: 8.4] [Reference Citation Analysis]
552 Goulart AC, Oliveira IR, Alencar AP, Santos MS, Santos IS, Martines BM, Meireles DP, Martines JA, Misciagna G, Benseñor IM, Lotufo PA. Diagnostic accuracy of a noninvasive hepatic ultrasound score for non-alcoholic fatty liver disease (NAFLD) in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Sao Paulo Med J 2015;133:115-24. [PMID: 26018881 DOI: 10.1590/1516-3180.2014.9150812] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
553 Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015;5:7-13. [PMID: 26528424 DOI: 10.15280/jlm.2015.5.1.7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
554 Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol 2015; 7(3): 575-582 [PMID: 25848481 DOI: 10.4254/wjh.v7.i3.575] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
555 Sanal MG. Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes? World J Gastroenterol 2015; 21(11): 3223-3231 [PMID: 25805928 DOI: 10.3748/wjg.v21.i11.3223] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
556 Fuchs M. New Medical Treatment Strategies for Nonalcoholic Steatohepatitis. Curr Treat Options Gastro 2015;13:259-73. [DOI: 10.1007/s11938-015-0053-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
557 Paschetta E, Belci P, Alisi A, Liccardo D, Cutrera R, Musso G, Nobili V. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm. 2015;2015:815721. [PMID: 25873773 DOI: 10.1155/2015/815721] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
558 Tai FW, Syn WK, Alazawi W. Practical approach to non-alcoholic fatty liver disease in patients with diabetes. Diabet Med. 2015; Feb 12. [Epub ahead of print]. [PMID: 25683343 DOI: 10.1111/dme.12725] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
559 Gitto S, Vitale G, Villa E, Andreone P. Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract. 2015;2015:732870. [PMID: 25866507 DOI: 10.1155/2015/732870] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
560 Alkhouri N, Alisi A, Okwu V, Matloob A, Ferrari F, Crudele A, De Vito R, Lopez R, Feldstein AE, Nobili V. Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. Dig Dis Sci. 2015;60:2353-2359. [PMID: 25764498 DOI: 10.1007/s10620-015-3614-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
561 Agrawal S, Duseja A, Aggarwal A, Das A, Mehta M, Dhiman RK, Chawla Y. Obstructive sleep apnea is an important predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease in a tertiary care center. Hepatol Int. 2015;9:283-291. [PMID: 25788200 DOI: 10.1007/s12072-015-9615-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
562 Wong GL, Chan HL. Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. Hepatol Int 2015;9:481-3. [DOI: 10.1007/s12072-015-9625-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
563 Williams KH, Viera de Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Bu Y, Brooks B, Cavanagh E, Raleigh J, McLennan SV, McCaughan GW, Bachovchin WW, Keane FM, Zekry A, Twigg SM, Gorrell MD. Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. Diabetes Res Clin Pract 2015;108:466-72. [PMID: 25836944 DOI: 10.1016/j.diabres.2015.02.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
564 AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev 2015;16:393-405. [PMID: 25753407 DOI: 10.1111/obr.12271] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
565 Pacana T, Sanyal AJ. Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000Prime Rep. 2015;7:28. [PMID: 25926979 DOI: 10.12703/p7-28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
566 Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease 2015;47:181-90. [DOI: 10.1016/j.dld.2014.09.020] [Cited by in Crossref: 443] [Cited by in F6Publishing: 409] [Article Influence: 63.3] [Reference Citation Analysis]
567 Zelber-sagi S, Salomone F, Webb M, Lotan R, Yeshua H, Halpern Z, Santo E, Oren R, Shibolet O. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Translational Research 2015;165:428-36. [DOI: 10.1016/j.trsl.2014.10.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
568 Diehl DL, Johal AS, Khara HS, Stavropoulos SN, Al-Haddad M, Ramesh J, Varadarajulu S, Aslanian H, Gordon SR, Shieh FK, Pineda-Bonilla JJ, Dunkelberger T, Gondim DD, Chen EZ. Endoscopic ultrasound-guided liver biopsy: a multicenter experience. Endosc Int Open. 2015;3:E210-E215. [PMID: 26171433 DOI: 10.1055/s-0034-1391412] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
569 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
570 Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Pai RK, Yerian L, Khiyami A, Sourianarayanane A, Sargent R, Hawkins C, Dasarathy S, McCullough AJ. Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic Fatty liver disease. Dig Dis Sci. 2015;60:1825-1831. [PMID: 25708897 DOI: 10.1007/s10620-015-3529-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
571 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 135] [Cited by in F6Publishing: 71] [Article Influence: 19.3] [Reference Citation Analysis]
572 Yamasaki Y, Nouso K, Miyahara K, Wada N, Dohi C, Morimoto Y, Kinugasa H, Takeuchi Y, Yasunaka T, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Iwasaki Y, Amano M, Nishimura S, Yamamoto K. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis: Glycan markers for fatty liver diseases. J Gastroenterol Hepatol 2015;30:528-34. [DOI: 10.1111/jgh.12726] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
573 Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol. 2015;5:147-158. [PMID: 26155043 DOI: 10.1016/j.jceh.2015.02.002] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 10.0] [Reference Citation Analysis]
574 Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, Motta BM, Kaminska D, Rametta R, Grimaudo S, Pelusi S, Montalcini T, Alisi A, Maggioni M, Kärjä V, Borén J, Käkelä P, Di Marco V, Xing C, Nobili V, Dallapiccola B, Craxi A, Pihlajamäki J, Fargion S, Sjöström L, Carlsson LM, Romeo S, Valenti L. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015;61:506-14. [PMID: 25251399 DOI: 10.1002/hep.27490] [Cited by in Crossref: 322] [Cited by in F6Publishing: 306] [Article Influence: 46.0] [Reference Citation Analysis]
575 Acharya UR, Faust O, Molinari F, Sree SV, Junnarkar SP, Sudarshan V. Ultrasound-based tissue characterization and classification of fatty liver disease: A screening and diagnostic paradigm. Knowledge-Based Systems 2015;75:66-77. [DOI: 10.1016/j.knosys.2014.11.021] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
576 Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients. J Viral Hepat 2015;22:800-8. [DOI: 10.1111/jvh.12394] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
577 Dyson JK, McPherson S, Anstee QM. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgrad Med J. 2014;90:254-266. [PMID: 24737902 DOI: 10.1136/postgradmedj-2013-201620rep] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
578 Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol. 2015;8:1-9. [PMID: 25575848 DOI: 10.1007/s12328-014-0548-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
579 Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Kanemasa K, Yasui K, Minami M, Imai S, Itoh Y. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients: ALT in NASH progression. Hepatol Res 2015;45:E53-61. [DOI: 10.1111/hepr.12456] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
580 Patel K, Shackel NA. Current status of fibrosis markers. Curr Opin Gastroenterol. 2014;30:253-259. [PMID: 24671009 DOI: 10.1097/mog.0000000000000059] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
581 Williams KH, Vieira De Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Brooks B, Bu Y, Cavanagh E, Raleigh J, McLennan SV. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study. J Diabetes. 2015;7:809-819. [PMID: 25350950 DOI: 10.1111/1753-0407.12237] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
582 Zhang B, Ding F, Chen T, Xia LH, Qian J, Lv GY. Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content. World J Gastroenterol 2014; 20(47): 17985-17992 [PMID: 25548498 DOI: 10.3748/wjg.v20.i47.17985] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
583 Bo S, Gambino R, Menato G, Canil S, Ponzo V, Pinach S, Durazzo M, Ghigo E, Cassader M, Musso G. Isoleucine-to-methionine substitution at residue 148 variant of PNPLA3 gene and metabolic outcomes in gestational diabetes. Am J Clin Nutr 2015;101:310-8. [PMID: 25646328 DOI: 10.3945/ajcn.114.095125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
584 Mueller NT, Pereira MA, Demerath EW, Dreyfus JG, MacLehose RF, Carr JJ, Terry JG, Jacobs DR Jr. Earlier menarche is associated with fatty liver and abdominal ectopic fat in midlife, independent of young adult BMI: The CARDIA study. Obesity (Silver Spring) 2015;23:468-74. [PMID: 25521620 DOI: 10.1002/oby.20950] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
585 Junker AE, Gluud LL, Pedersen J, Langhoff JL, Holst JJ, Knop FK, Vilsbøll T. A 25-year-old woman with type 2 diabetes and liver disease. Case Rep Gastroenterol 2014;8:398-403. [PMID: 25606030 DOI: 10.1159/000369968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
586 Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014; 20(45): 16820-16830 [PMID: 25492996 DOI: 10.3748/wjg.v20.i45.16820] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 89] [Article Influence: 13.6] [Reference Citation Analysis]
587 Chan W, Nik Mustapha NR, Mahadeva S. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis. Hepatol Int 2015;9:594-602. [DOI: 10.1007/s12072-014-9596-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
588 Lin SC, Heba E, Wolfson T, Ang B, Gamst A, Han A, Erdman JW, O'Brien WD, Andre MP, Sirlin CB, Loomba R. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique. Clin Gastroenterol Hepatol. 2015;13:1337-1345.e6. [PMID: 25478922 DOI: 10.1016/j.cgh.2014.11.027] [Cited by in Crossref: 146] [Cited by in F6Publishing: 131] [Article Influence: 18.3] [Reference Citation Analysis]
589 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:475-485. [PMID: 24574716 DOI: 10.3748/wpg.v20.i2.475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
590 Fares R, Petta S, Lombardi R, Grimaudo S, Dongiovanni P, Pipitone R, Rametta R, Fracanzani AL, Mozzi E, Craxì A. The UCP2 -866 G& gt; A promoter region polymorphism is associated with nonalcoholic steatohepatitis. Liver Int. 2015;35:1574-1580. [PMID: 25351290 DOI: 10.1111/liv.12707] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
591 Vander Naalt SJ, Gurria JP, Holterman AL. Surgical treatment of nonalcoholic fatty liver disease in severely obese patients. Hepat Med 2014;6:103-12. [PMID: 25378958 DOI: 10.2147/HMER.S64819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
592 Ma H, Cui F, Dong JJ, You GP, Yang XJ, Lu HD, Huang YL. Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(40): 14950-14957 [PMID: 25356056 DOI: 10.3748/wjg.v20.i40.14950] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
593 Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, Romagnoli D, Loria P. Nonalcoholic fatty liver disease and aging: Epidemiology to management. World J Gastroenterol 2014; 20(39): 14185-14204 [PMID: 25339806 DOI: 10.3748/wjg.v20.i39.14185] [Cited by in CrossRef: 163] [Cited by in F6Publishing: 142] [Article Influence: 20.4] [Reference Citation Analysis]
594 Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2015;9:629-50. [DOI: 10.1586/17474124.2015.965143] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 7.1] [Reference Citation Analysis]
595 Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28 Suppl 4:64-70. [PMID: 24251707 DOI: 10.1111/jgh.12271] [Cited by in Crossref: 117] [Cited by in F6Publishing: 136] [Article Influence: 14.6] [Reference Citation Analysis]
596 Olaywi M, Bhatia T, Anand S, Singhal S. Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. Hepatobiliary Pancreat Dis Int. 2013;12:584-588. [PMID: 24322742 DOI: 10.1016/S1499-3872(13)60092-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
597 Seko Y, Sumida Y, Tanaka S, Taketani H, Kanemasa K, Ishiba H, Okajima A, Nishimura T, Yamaguchi K, Moriguchi M. Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease. Hepatol Res. 2015;45:728-738. [PMID: 25165040 DOI: 10.1111/hepr.12407] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
598 Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V; LIDO Study Group. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1209-1222. [PMID: 25267215 DOI: 10.1111/apt.12963] [Cited by in Crossref: 204] [Cited by in F6Publishing: 194] [Article Influence: 25.5] [Reference Citation Analysis]
599 Mitchel EB, Lavine JE. Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1155-1170. [PMID: 25267322 DOI: 10.1111/apt.12972] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
600 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 2014; 20(36): 12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 122] [Cited by in F6Publishing: 103] [Article Influence: 15.3] [Reference Citation Analysis]
601 Xin YN, Geng N, Lin ZH, Cui YZ, Duan HP, Zhang M, Xuan SY. Serum complement C3f and fibrinopeptide A are potential novel diagnostic biomarkers for non-alcoholic fatty liver disease: a study in Qingdao Twins. PLoS One 2014;9:e108132. [PMID: 25250770 DOI: 10.1371/journal.pone.0108132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
602 Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, Clark L, Hooker J, Chavez T, Ang BD, Middleton MS, Peterson M, Loomba R, Sirlin CB. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 2015;274:416-25. [PMID: 25247408 DOI: 10.1148/radiol.14140754] [Cited by in Crossref: 131] [Cited by in F6Publishing: 145] [Article Influence: 16.4] [Reference Citation Analysis]
603 Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, Sourianarayanane A, Khiyami A, Yerian L, Pai RK, Dasarathy S, McCullough AJ. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin. 2015;3:141-145. [PMID: 26675585 DOI: 10.1016/j.bbacli.2014.09.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
604 Hassan K, Bhalla V, Regal MEE, A-Kader HH. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20(34): 12082-12101 [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 122] [Cited by in F6Publishing: 110] [Article Influence: 15.3] [Reference Citation Analysis]
605 Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, Cha BS, Lee HC, Balkau B, Lee WY, Kim DJ. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One 2014;9:e107584. [PMID: 25216184 DOI: 10.1371/journal.pone.0107584] [Cited by in Crossref: 45] [Cited by in F6Publishing: 60] [Article Influence: 5.6] [Reference Citation Analysis]
606 Keramida G, Potts J, Bush J, Verma S, Dizdarevic S, Peters AM. Accumulation of 18 F-FDG in the Liver in Hepatic Steatosis. American Journal of Roentgenology 2014;203:643-8. [DOI: 10.2214/ajr.13.12147] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
607 Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31): 10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 62] [Article Influence: 8.9] [Reference Citation Analysis]
608 Kanerva N, Sandboge S, Kaartinen NE, Männistö S, Eriksson JG. Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. Am J Clin Nutr. 2014;100:1133-1138. [PMID: 25099548 DOI: 10.3945/ajcn.114.086074] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
609 Bedossa P; FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014;60:565-75. [PMID: 24753132 DOI: 10.1002/hep.27173] [Cited by in Crossref: 345] [Cited by in F6Publishing: 304] [Article Influence: 43.1] [Reference Citation Analysis]
610 Lee SS, Byoun YS, Jeong SH, Woo BH, Jang ES, Kim JW, Kim HY. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea. Dig Dis Sci. 2014;59:2967-2974. [PMID: 25069572 DOI: 10.1007/s10620-014-3279-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
611 Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ 2014;349:g4596. [PMID: 25239614 DOI: 10.1136/bmj.g4596] [Cited by in Crossref: 157] [Cited by in F6Publishing: 169] [Article Influence: 19.6] [Reference Citation Analysis]
612 Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliðadóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680. [PMID: 25050550 DOI: 10.1371/journal.pmed.1001680] [Cited by in Crossref: 283] [Cited by in F6Publishing: 342] [Article Influence: 35.4] [Reference Citation Analysis]
613 Bedogni G, Nobili V, Tiribelli C. Epidemiology of fatty liver: An update. World J Gastroenterol 2014; 20(27): 9050-9054 [PMID: 25083078 DOI: 10.3748/wjg.v20.i27.9050] [Cited by in F6Publishing: 43] [Reference Citation Analysis]
614 Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age? World J Gastroenterol 2014; 20(27): 9072-9089 [PMID: 25083080 DOI: 10.3748/wjg.v20.i27.9072] [Cited by in F6Publishing: 56] [Reference Citation Analysis]
615 Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765-783.e4. [PMID: 25046161 DOI: 10.1053/j.gastro.2014.07.018] [Cited by in Crossref: 365] [Cited by in F6Publishing: 397] [Article Influence: 45.6] [Reference Citation Analysis]
616 Leite NC, Villela-Nogueira CA, Cardoso CRL, Salles GF. Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014; 20(26): 8377-8392 [PMID: 25024596 DOI: 10.3748/wjg.v20.i26.8377] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 39] [Article Influence: 6.5] [Reference Citation Analysis]
617 Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637-653. [PMID: 25194181 DOI: 10.1016/j.bpg.2014.07.008] [Cited by in Crossref: 189] [Cited by in F6Publishing: 213] [Article Influence: 23.6] [Reference Citation Analysis]
618 Losekann A, Weston AC, Carli LA, Espindola MB, Pioner SR, Coral GP. Nonalcoholic fatty liver disease in severe obese patients, subjected to bariatric surgery. Arq Gastroenterol. 2013;50:285-289. [PMID: 24474231 DOI: 10.1590/s0004-28032013000400009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
619 van Enst WA, Scholten RJ, Whiting P, Zwinderman AH, Hooft L. Meta-epidemiologic analysis indicates that MEDLINE searches are sufficient for diagnostic test accuracy systematic reviews. J Clin Epidemiol 2014;67:1192-9. [PMID: 24996667 DOI: 10.1016/j.jclinepi.2014.05.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
620 Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep 2014;2:633-6. [PMID: 25054002 DOI: 10.3892/br.2014.309] [Cited by in Crossref: 51] [Cited by in F6Publishing: 59] [Article Influence: 6.4] [Reference Citation Analysis]
621 Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309. [PMID: 24978903 DOI: 10.1038/ncomms5309] [Cited by in Crossref: 307] [Cited by in F6Publishing: 333] [Article Influence: 38.4] [Reference Citation Analysis]
622 Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver. Exp Ther Med 2014;8:759-62. [PMID: 25120595 DOI: 10.3892/etm.2014.1798] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
623 VanWagner LB, Ning H, Lewis CE, Shay CM, Wilkins J, Carr JJ, Terry JG, Lloyd-Jones DM, Jacobs DR Jr, Carnethon MR. Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study. Atherosclerosis. 2014;235:599-605. [PMID: 24956534 DOI: 10.1016/j.atherosclerosis.2014.05.962] [Cited by in Crossref: 90] [Cited by in F6Publishing: 107] [Article Influence: 11.3] [Reference Citation Analysis]
624 Bedogni G, Gastaldelli A, Tiribelli C, Agosti F, De Col A, Fessehatsion R, Sartorio A. Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. J Endocrinol Invest 2014;37:739-44. [PMID: 24906975 DOI: 10.1007/s40618-014-0101-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
625 Caballería L, Saló J, Berzigotti A, Planas R, Vila C, Huertas C, Torres M, Torán P, Caballería J. Hígado graso no alcohólico. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2014;37:372-83. [DOI: 10.1016/j.gastrohep.2014.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
626 Anstee QM, Jaques B, Hudson M, Reeves HL. Reply to “Hepatocellular carcinoma and the Newcastle-upon-Tyne area”. Journal of Hepatology 2014;60:1330-1. [DOI: 10.1016/j.jhep.2014.02.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
627 Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol 2014; 6(5): 263-273 [PMID: 24868320 DOI: 10.4254/wjh.v6.i5.263] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 10.1] [Reference Citation Analysis]
628 Grabe HJ, Assel H, Bahls T, Dörr M, Endlich K, Endlich N, Erdmann P, Ewert R, Felix SB, Fiene B, Fischer T, Flessa S, Friedrich N, Gadebusch-Bondio M, Salazar MG, Hammer E, Haring R, Havemann C, Hecker M, Hoffmann W, Holtfreter B, Kacprowski T, Klein K, Kocher T, Kock H, Krafczyk J, Kuhn J, Langanke M, Lendeckel U, Lerch MM, Lieb W, Lorbeer R, Mayerle J, Meissner K, zu Schwabedissen HM, Nauck M, Ott K, Rathmann W, Rettig R, Richardt C, Saljé K, Schminke U, Schulz A, Schwab M, Siegmund W, Stracke S, Suhre K, Ueffing M, Ungerer S, Völker U, Völzke H, Wallaschofski H, Werner V, Zygmunt MT, Kroemer HK. Cohort profile: Greifswald approach to individualized medicine (GANI_MED). J Transl Med 2014;12:144. [PMID: 24886498 DOI: 10.1186/1479-5876-12-144] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
629 Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45:20-28. [PMID: 24661406 DOI: 10.1111/hepr.12333] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 7.1] [Reference Citation Analysis]
630 Petta S, Vanni E, Bugianesi E, Di Marco V, Cammà C, Cabibi D, Mezzabotta L, Craxì A. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2015;35:1566-1573. [PMID: 24798049 DOI: 10.1111/liv.12584] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 10.1] [Reference Citation Analysis]
631 Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2121-30.e1-2. [PMID: 24846279 DOI: 10.1016/j.cgh.2014.05.010] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 9.4] [Reference Citation Analysis]
632 Heianza Y, Arase Y, Tsuji H, Fujihara K, Saito K, Hsieh SD, Tanaka S, Kodama S, Hara S, Sone H. Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20). J Clin Endocrinol Metab. 2014;99:2952-2960. [PMID: 24823457 DOI: 10.1210/jc.2013-4427] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 7.4] [Reference Citation Analysis]
633 Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2014;15:7352-7379. [PMID: 24786095 DOI: 10.3390/ijms15057352] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 9.9] [Reference Citation Analysis]
634 Pulixi EA, Tobaldini E, Battezzati PM, D’Ingianna P, Borroni V, Fracanzani AL, Maggioni M, Pelusi S, Bulgheroni M, Zuin M. Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease. PLoS One. 2014;9:e96349. [PMID: 24763757 DOI: 10.1371/journal.pone.0096349] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
635 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20(15): 4300-4315 [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 61] [Article Influence: 8.8] [Reference Citation Analysis]
636 Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014;34:1155-1161. [PMID: 24743428 DOI: 10.1161/atvbaha.114.303034] [Cited by in Crossref: 96] [Cited by in F6Publishing: 93] [Article Influence: 12.0] [Reference Citation Analysis]
637 Arteaga I, Buezo I, Expósito C, Pera G, Rodríguez L, Alumà A, Auladell MA, Torán P, Caballería L. [Non-invasive markers of fibrosis in the diagnosis of non-alcoholic fatty liver disease]. Gastroenterol Hepatol 2014;37:503-10. [PMID: 24746708 DOI: 10.1016/j.gastrohep.2014.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
638 Mohammadi F, Qorbani M, Kelishadi R, Baygi F, Ardalan G, Taslimi M, Mahmoudarabi M, Motlagh M, Asayesh H, Larijani B, Heshmat R. Association of Cardiometabolic Risk Factors and Hepatic Enzymes in a National Sample of Iranian Children and Adolescents: The CASPIAN-III Study. Journal of Pediatric Gastroenterology & Nutrition 2014;58:463-8. [DOI: 10.1097/mpg.0000000000000246] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
639 Choi W, Lee J, Yoon J, Kwak C, Lee YJ, Cho YY, Lee YB, Yu SJ, Kim YJ, Kim HH, Kim H, Cho SY, Lee SB, Jeong H, Kim CY, Lee H. Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocrine-Related Cancer 2014;21:343-53. [DOI: 10.1530/erc-14-0036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
640 Alkhouri N, McCullough AJ. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8:661-668. [PMID: 24683373 DOI: 10.1016/s0016-5085(10)62097-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
641 Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol. 2014;8:487-500. [PMID: 24665862 DOI: 10.1586/17474124.2014.903798] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
642 Karlas T, Petroff D, Garnov N, Böhm S, Tenckhoff H, Wittekind C, Wiese M, Schiefke I, Linder N, Schaudinn A. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One. 2014;9:e91987. [PMID: 24637477 DOI: 10.1371/journal.pone.0091987] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 10.0] [Reference Citation Analysis]
643 Lahmek P, Meunier N, Michel L, Aubin H, Balester-mouret S. Utilisation de l’élastométrie hépatique comme outil de dépistage de la fibrose hépatique dans un service d’addictologie. La Presse Médicale 2014;43:e17-31. [DOI: 10.1016/j.lpm.2013.07.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
644 Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014;59:1174-97. [PMID: 24002776 DOI: 10.1002/hep.26717] [Cited by in Crossref: 351] [Cited by in F6Publishing: 326] [Article Influence: 43.9] [Reference Citation Analysis]
645 López-velázquez JA, Silva-vidal KV, Ponciano-rodríguez G, Chávez-tapia NC, Arrese M, Uribe M, Méndez-sánchez N. The prevalence of nonalcoholic fatty liver disease in the Americas. Annals of Hepatology 2014;13:166-78. [DOI: 10.1016/s1665-2681(19)30879-8] [Cited by in Crossref: 82] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
646 Sung K, Cha S, Sung J, So M, Byrne CD. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutrition, Metabolism and Cardiovascular Diseases 2014;24:256-62. [DOI: 10.1016/j.numecd.2013.07.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
647 Sheldon RD, Laughlin MH, Rector RS. Reduced hepatic eNOS phosphorylation is associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise in hyperphagic OLETF rats. J Appl Physiol (1985) 2014;116:1156-64. [PMID: 24577062 DOI: 10.1152/japplphysiol.01275.2013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
648 Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1756-1767 [PMID: 24587653 DOI: 10.3748/wjg.v20.i7.1756] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 65] [Article Influence: 8.6] [Reference Citation Analysis]
649 Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1724-1745 [PMID: 24587651 DOI: 10.3748/wjg.v20.i7.1724] [Cited by in CrossRef: 154] [Cited by in F6Publishing: 143] [Article Influence: 19.3] [Reference Citation Analysis]
650 Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep 2014;13:151-8. [PMID: 24977111 DOI: 10.1007/s11901-014-0227-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
651 Musso G. Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD? Diabetologia. 2014;57:850-855. [PMID: 24554006 DOI: 10.1007/s00125-014-3192-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
652 Ozenirler S, Erkan G, Konca Degertekin C, Ercin U, Cengiz M, Bilgihan A, Yilmaz G, Akyol G. The relationship between advanced oxidation protein products (AOPP) and biochemical and histopathological findings in patients with nonalcoholic steatohepatitis: AOPP and nonalcoholic steatohepatitis. Journal of Digestive Diseases 2014;15:131-6. [DOI: 10.1111/1751-2980.12113] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
653 Holterman A, Gurria J, Tanpure S, Disomma N. Nonalcoholic fatty liver disease and bariatric surgery in adolescents. Seminars in Pediatric Surgery 2014;23:49-57. [DOI: 10.1053/j.sempedsurg.2013.10.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
654 Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 2014;63:161-7. [DOI: 10.1016/j.metabol.2013.10.010] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
655 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20(2): 475-485 [PMID: 24574716 DOI: 10.3748/wjg.v20.i2.475] [Cited by in CrossRef: 314] [Cited by in F6Publishing: 286] [Article Influence: 39.3] [Reference Citation Analysis]
656 Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014;60:1063-1074. [PMID: 24412608 DOI: 10.1016/j.jhep.2013.12.026] [Cited by in Crossref: 109] [Cited by in F6Publishing: 120] [Article Influence: 13.6] [Reference Citation Analysis]
657 Ye Z, Wang S, Yang Z, He M, Zhang S, Zhang W, Wen J, Li Q, Huang Y, Wang X, Lu B, Zhang Z, Su Q, Hu R. Serum lipocalin-2, cathepsin S and chemerin levels and nonalcoholic fatty liver disease. Mol Biol Rep 2014;41:1317-23. [PMID: 24390241 DOI: 10.1007/s11033-013-2977-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
658 Francque SM. The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. Eur Cardiol 2014;9:10-5. [PMID: 30310479 DOI: 10.15420/ecr.2014.9.1.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
659 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 8.3] [Reference Citation Analysis]
660 van der Voort EA, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HL, Schouten JN, Nijsten T. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70:517-524. [PMID: 24373781 DOI: 10.1016/j.jaad.2013.10.044] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
661 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211-8. [PMID: 25018867 DOI: 10.1136/flgastro-2013-100403] [Cited by in Crossref: 166] [Cited by in F6Publishing: 158] [Article Influence: 18.4] [Reference Citation Analysis]
662 Lu ML, Huang H, Liu LM, Chang J. The Relationship between Intestinal Motility and Interstitial Cells of Cajal in Nonalcoholic Fatty Liver Mice. Hepat Mon 2013;13:e13674. [PMID: 24348640 DOI: 10.5812/hepatmon.13674] [Reference Citation Analysis]
663 Chang Y, Jung H, Yun KE, Cho J, Cho YK, Ryu S. Cohort Study of Non-alcoholic Fatty Liver Disease, NAFLD fibrosis score, and the Risk of Incident Diabetes in a Korean population. American Journal of Gastroenterology 2013;108:1861-8. [DOI: 10.1038/ajg.2013.349] [Cited by in Crossref: 103] [Cited by in F6Publishing: 108] [Article Influence: 11.4] [Reference Citation Analysis]
664 Pappachan JM, Antonio FA, Edavalath M, Mukherjee A. Non-alcoholic fatty liver disease: a diabetologist's perspective. Endocrine 2014;45:344-53. [PMID: 24287794 DOI: 10.1007/s12020-013-0087-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
665 Hecht L, Weiss R. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Obese Children. Curr Diab Rep 2014;14. [DOI: 10.1007/s11892-013-0448-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
666 Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013;14:22933-22966. [PMID: 24264040 DOI: 10.3390/ijms141122933] [Cited by in Crossref: 62] [Cited by in F6Publishing: 70] [Article Influence: 6.9] [Reference Citation Analysis]
667 Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013; 19(41): 6969-6978 [PMID: 24222941 DOI: 10.3748/wjg.v19.i41.6969] [Cited by in CrossRef: 151] [Cited by in F6Publishing: 145] [Article Influence: 16.8] [Reference Citation Analysis]
668 Yao Z, Liu XC, Gu YE. Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats. Afr J Tradit Complement Altern Med 2014;11:222-7. [PMID: 24653581 DOI: 10.4314/ajtcam.v11i1.35] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
669 Armstrong MJ, Hazlehurst JM, Parker R, Koushiappi E, Mann J, Khan S, Philips A, Chandler L, Johnson J, Round M, Haydon G, Karamat MA, Newsome PN, Tomlinson JW. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM 2014;107:33-41. [PMID: 24131545 DOI: 10.1093/qjmed/hct198] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
670 Kim HM, Kim BS, Cho YK, Kim BI, Sohn CI, Jeon WK, Kim HJ, Park DI, Park JH, Joo KJ. Elevated red cell distribution width is associated with advanced fibrosis in NAFLD. Clin Mol Hepatol. 2013;19:258-265. [PMID: 24133663 DOI: 10.3350/cmh.2013.19.3.258] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
671 Boland BS, Edelman SV, Wolosin JD. Gastrointestinal complications of diabetes. Endocrinol Metab Clin North Am 2013;42:809-32. [PMID: 24286951 DOI: 10.1016/j.ecl.2013.07.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
672 Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10:645-655. [PMID: 24061205 DOI: 10.1038/nrgastro.2013.182] [Cited by in Crossref: 223] [Cited by in F6Publishing: 206] [Article Influence: 24.8] [Reference Citation Analysis]
673 Musso G, Bo S, Cassader M, De Michieli F, Gambino R. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. Am J Clin Nutr. 2013;98:895-906. [PMID: 23985808 DOI: 10.3945/ajcn.113.063792] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
674 Gawrieh S, Chalasani N. NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials? Gastroenterology 2013;145:717-9. [PMID: 23973850 DOI: 10.1053/j.gastro.2013.08.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
675 Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:167-174. [PMID: 23973932 DOI: 10.1016/j.jhep.2013.07.042] [Cited by in Crossref: 154] [Cited by in F6Publishing: 149] [Article Influence: 17.1] [Reference Citation Analysis]
676 Corey KE, Chalasani N. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:1077-84; quiz e59-60. [PMID: 23962548 DOI: 10.1016/j.cgh.2013.08.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
677 Trembling PM, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M, Rosenberg WM. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 2014;21:430-8. [PMID: 24750297 DOI: 10.1111/jvh.12161] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
678 Dyson JK, Mcpherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.